Download Developing Cures, Creating Jobs

Developing Cures,
Creating Jobs
A Partnership Between Biopharmaceutical
Companies And State Research Institutions
PHARMACEUTICAL CLINICAL TRIALS IN
GEORGIA
Executive Summary
This report shows that biopharmaceutical research companies continue to be vitally important to the economy
and patient health in Georgia, despite the recession.
the Peach State—are helping to advance science and patient
care since many involve cutting-edge, new-generation
biotechnology medications.
At a time when the state still faces significant economic
challenges, these companies are conducting or have
conducted more than 3,600 clinical trials of new medicines in collaboration with the state’s university medical
schools, hospitals and clinical research centers. Of the more
than 3,600 clinical trials, 1,800 target or have targeted the
nation’s six most debilitating chronic diseases—asthma,
cancer, diabetes, heart disease, mental illnesses and stroke.
Earlier reports have shown the nation’s biopharmaceutical
companies are also an important source of jobs, research
spending and tax revenue. A study by Archstone Consulting, for example, found that the industry supported nearly
55,000 Georgia jobs in 2008 and was responsible for
providing $11.1 billion in products and services.
Institutions involved in clinical tests of treatments
include the Medical College of Georgia in Augusta and
the Emory University School of Medicine in Atlanta;
such research centers as the Atlanta’s Women’s Research
Institute and the Piedmont Hospital Research Institute
in Atlanta; and hospitals like Phoebe Putney Memorial
Hospital in Albany and Northeast Georgia Medical
Center in Gainesville.
The biopharmaceutical drug trials provide steady revenue
for research facilities all over the state and what’s more,
nearly 400 of the clinical tests for the six chronic diseases
are in the initial stages of recruiting patients, which could
be important to those still seeking effective treatments. In
addition, these tests—which are being conducted all over
2
Biopharmaceutical company employees in the state
include life sciences researchers, management executives, office and administrative support workers, production workers, engineers, architects, computer and math
experts and sales representatives.
In 2008, these workers were paid an estimated
$338.4 million, leading to more than $15 million in
state taxes and more than $81 million in federal taxation.
Biopharmaceutical research firms that year also invested
$491.3 million in research and development in the state.
This new clinical trial report shows three years later, the
trend continues: American biopharmaceutical research
companies remain vitally important to the residents and
economy of Georgia.
PhRMA • PHARMACEUTICAL CLINICAL TRIALS IN GEORGIA
The Need for New
Chronic Disease Medicines
Chronic diseases pose the greatest threats to our nation’s
health and our ability to treat and prevent medical conditions. According to the Centers for Disease Control and
Prevention, today, in the United States:
•
Patients with chronic diseases account for 75 cents
of every dollar spent on health care.
•
Chronic diseases are the leading cause of death and
disability.
•
Chronic diseases are a leading driver of rising health
care costs with expenses totaling billions of dollars
every year.
With the stakes so high, America’s biopharmaceutical research companies are developing new medicines to help
treat those conditions that are taking an unprecedented
toll on American lives.
Many of these medicines are being tested today in clinical
trials throughout Georgia.
At a time when tens of thousands of state residents are
suffering from one or more chronic diseases, America’s
biopharmaceutical research companies are sponsoring
or have sponsored 1,800 clinical trials of potential new
medicines in the Peach State alone for asthma, cancer,
heart disease, stroke, diabetes and mental illnesses. Of the
1,800 trials, nearly 400 are either not yet recruiting or are
just now seeking Georgia patients, thus giving those still
searching for effective treatments potential new options.
Many of the state’s clinical tests involve collaborations
with such respected local institutions as the Emory
University School of Medicine in Atlanta, the Medical
College of Georgia in Augusta, the Cancer Center
at DeKalb Medical, Memorial Health University
Medical Center in Savannah, and the Atlanta VA
Medical Center.
DEVELOPING CURES, CREATING JOBS • A PARTNERSHIP BETWEEN BIOPHARMACEUTICAL COMPANIES AND STATE RESEARCH INSTITUTIONS
3
Clinical Trials in Georgia
Table 1. Clinical Trials in Georgia for
Selected Chronic Diseases
Chronic Disease
All Clinical Trials
Clinical Trials
Still Recruiting
Asthma
63
13
Cancer
813
200
Diabetes
303
42
Heart Disease
146
33
Mental Illness
439
87
Stroke
36
12
Source: www.clinicaltrials.gov
Note: Search criteria = Georgia, Phase I, II, III; industry only.
Search performed 10/31/2011
Clinical tests of new medicines are a vitally important part
of the drug development and approval process—they account for 45 to 75 percent of the $1.2 billion average cost
of developing a new drug and are conducted to determine
the safety and effectiveness of that treatment in patients.
Some trials are also conducted to compare existing treatments and some are done to learn if a drug is appropriate
for a different patient population, such as children. Still
others are conducted to find ways to make existing approved drugs more effective and easier to use with fewer
side effects.
4
It’s essential that trials be conducted properly so that
clinicians and drug reviewers can develop accurate assessments of the efficacy and safety of medicines when used
by patients.The Food and Drug Administration (FDA) is
a vigilant regulatory agency and its pharmaceutical review
officers are effective in detecting flawed information.
Questionable or confusing data can lead to lengthy
delays in product approval or outright FDA rejection
of a new drug.
Biopharmaceutical research companies are looking for
the best physicians and research institutions to meticulously help design and conduct their clinical trials to
determine whether a medicine is safe and effective.
Side effects must be painstakingly documented and a
determination made as to whether they occur too often
and are dangerous.
Clinical tests involve three phases and thousands of
volunteer patients and are often conducted at multiple
sites around the country. In Georgia, biopharmaceutical
companies have the luxury of having trials conducted
at the states’ well-respected university medical schools,
comprehensive cancer centers and clinical trial research
centers. According to U.S. News and World Report,
Emory University School of Medical ranked 21st and
the Medical College of Georgia ranked 71st among this
year’s top 100 research-oriented medical schools in the
United States.
PhRMA • PHARMACEUTICAL CLINICAL TRIALS IN GEORGIA
Asthma is a debilitating condition for more than
Heart disease and stroke are the first and fourth
23 million Americans, including 7 million children
under the age of 18. The toll is also severe in Georgia
—in 2010, approximately 600,000 adults and 297,000
children had asthma, according to the Georgia Department of Community Health.
leading disease causes of death in the United States and
the first and third in Georgia. According to the American
Heart Association, more than 82 million Americans are
affected by these diseases. In Georgia, in 2008, more
than 21,000 residents died from some form of heart
disease and 3,775 died from a stroke, according to the
Georgia Department of Community Health.
Currently, 18 clinical trials of new asthma medicines are
recruiting patients in Georgia. Trials are being conducted
at Aeroallergy Research Laboratories of Savannah,
DataQuest Medical Research in Lawrenceville, and
Georgia Pollens Clinical Research Center in Albany.
Cancer, the second leading cause of death in the United
States, now afflicts nearly 12 million Americans, according to the National Cancer Institute. In Georgia, more
than 44,000 new cancer cases will be diagnosed this year
and 15,860 victims in the state will die, according to the
American Cancer Society.
Currently, 200 clinical trials of new cancer medicines are
recruiting patients in Georgia. Biopharmaceutical companies are collaborating on the tests with such prominent
institutions as the Atlanta’s Women’s Research Institute and the Winship Cancer Institute at Emory
University in Atlanta, Central Georgia Cancer Care
in Macon, the John B. Amos Cancer Center in
Columbus, the Nancy N. and J.C. Lewis Cancer
Center and Research Pavilion at St. Joseph/Candler
in Savannah, and Phoebe Putney Memorial Hospital
Cancer Center in Albany.
Diabetes affects more than 20 million Americans—
about 8 percent of the U.S. population—and nearly
one-third are unaware they have the disease. In 2008,
more than 1 million adults had diabetes in Georgia,
according to the Georgia Department of Community
Health.
Currently, 42 diabetes clinical tests are seeking patients in
Georgia. The trials are being conducted at Emory University, Middle Georgia Clinical Research Center
in Perry, Atlanta Diabetes Associates, and Atlanta
Pharmaceutical Research in Decatur.
Currently, 33 heart disease and 12 stroke clinical tests
are seeking patients in Georgia. The trials are being
conducted at the Emory Clinical-Crawford Long
Hospital and Morehouse School of Medicine in
Atlanta, Northeast Georgia Heart Institute in
Gainesville, Georgia Health Sciences University in
Augusta, Gwinnett Medical Center in Duluth, and
the Medical Center of Georgia in Macon.
Mental illness affects nearly 60 million Americans
suffering from some form of the disease—from anxiety
to depression to schizophrenia to eating disorders. In
Georgia, about 349,000 adults live with serious mental
illness and about 111,000 children live with serious
mental health conditions, according to the National
Alliance on Mental Illness.
Currently, 87 clinical trials are recruiting patients in
Georgia. The trials are taking place at the Atlanta
Center for Medical Research, the Atlanta VA
Medical Center, and Emory University in Atlanta,
the Institute for Behavioral Medicine in Smyrna,
the Medical College of Georgia in Augusta, and the
Northwest Behavioral Research Centers in Marietta
and Roswell.
Physicians and patients can find out about clinical trials being
conducted all over the state in collaboration with local institutions by accessing www.clinicaltrials.gov, a database sponsored
by the National Institutes of Health. Information on medicines
in development is also available on www.phrma.org, the
website of the Pharmaceutical Research and Manufacturers of
America (PhRMA).
DEVELOPING CURES, CREATING JOBS • A PARTNERSHIP BETWEEN BIOPHARMACEUTICAL COMPANIES AND STATE RESEARCH INSTITUTIONS
5
New Generation
Medicines in Development
Many of the medicines being tested in Georgia are
cutting-edge biotechnology drugs.
America’s biopharmaceutical research companies are
using biotechnology to develop hundreds of medicines
and vaccines today. And Georgia is one of the states
where new-generation research and development work
is being done.
Through biotechnology, new ways are being developed
to not only more effectively treat disease, but also to
predict, preempt and prevent it.
Biotechnology medicines are developed through biological processes using living cells or organisms, rather than
traditional chemical synthesis, the mainstay of pharmaceutical development for decades.
Such novel treatments use a variety of new approaches
to treat disease. For example, a monoclonal antibody is a
laboratory-made version of the naturally occurring immune system protein that binds to and neutralizes foreign
invaders. Interferons are proteins that interfere with the
ability of a cell to reproduce.
Antisense drugs, meanwhile, are medicines that interfere
with the communication process that tells a cell to produce an unwanted protein. In addition, nanotechnology
is being used in biotechnology research to provide drugdelivery systems, new treatments and diagnostics.
6
Many of the medicines in clinical testing at Georgia
medical schools and research centers feature these
technologies. For example:
•
A genetically-modified virus-based vaccine to treat
melanoma.
•
An antisense medicine for the treatment of cancer.
•
A recombinant fusion protein to treat age-related
macular degeneration and diabetic macular edema.
•
A monoclonal antibody in the pipeline targets lupus
and various types of cancer.
•
A therapeutic vaccine, designed to jump-start the
immune system to fight disease, is in development
for lung cancer and melanoma.
These are only a portion of the examples of new ways
the nation’s biopharmaceutical companies and Georgia
research institutions are working together to attack
disease. The biotechnology medicines and vaccines in
development promise to push the frontiers of science
and potentially bring more and better treatments to
patients.
PhRMA • PHARMACEUTICAL CLINICAL TRIALS IN GEORGIA
Conclusion
Biopharmaceutical companies’ close collaboration with
clinicians and research institutions in Georgia benefits
patients, the state’s economy and the advancement of
science and patient care. Clinical trial business is good
business for the state’s medical schools and clinical research centers and the medicines being tested are often
cutting-edge cell and protein treatments with the potential to be safer and more effective than older chemical
compound drugs.
What’s more, Georgians contemplating participation
in clinical trials have a wide range of choices—nearly
400 tests of new medicines for the six most debilitating
chronic diseases in America are underway in communities large and small all over the state and they need
patient volunteers. Additional clinical trials recruiting
patients target other diseases such as rheumatoid arthritis,
chronic obstructive pulmonary disease, traumatic brain
injury, cystic fibrosis, influenza, lupus, and psoriasis.
DEVELOPING CURES, CREATING JOBS • A PARTNERSHIP BETWEEN BIOPHARMACEUTICAL COMPANIES AND STATE RESEARCH INSTITUTIONS
7
The Drug Discovery, Development and Approval Process
It takes 10-15 years on average for an experimental drug to travel from the lab to U.S. patients. Only five in 5,000
compounds that enter preclinical testing make it to human testing. One of these five tested in people is approved.
Clinical Trials
Phase II
Phase III
FDA
Years
6.5
1.5
2
3.5
1.5
Test
Population
Laboratory and
animal studies
20 to 100
healthy
volunteers
100 to 500
patient
volunteers
1,000 to 5,000
patient
volunteers
Determine
safety
and dosage
Evaluate
effectiveness, look for
side effects
Confirm
effectiveness,
monitor adverse
­reactions from
long-term use
Purpose
Success
Rate
Assess safety,
biological activity
and formulations
5,000
compounds
evaluated
5
enter trials
File NDA/BLA at FDA
Phase I
File IND at FDA
Discovery/
Preclinical Testing
Review
process/
approval
Phase IV
Additional
postmarketing
testing
required
by FDA
1
approved
The Drug Development and Approval Process
The U.S. system of new drug approvals is
perhaps the most rigorous in the world.
It takes 10-15 years, on average, for an experimental drug to travel from lab to U.S. patients,
according to the Tufts Center for the Study of
Drug Development, based on drugs approved
from 1994 through 1998. Only five in 5,000
compounds that enter preclinical testing make
it to human testing. And only one of those five
is approved for sale.
On average, it costs a company $1.2 billion,
including the cost of failures, to get one new
medicine from the laboratory to U.S. patients,
according to a 2007 study by the Tufts Center
for the Study of Drug Development.
Once a new compound has been identified in
the laboratory, medicines are developed as
follows:
Preclinical Testing. A pharmaceutical company conducts laboratory and animal studies
to show biological activity of the compound
against the targeted disease, and the compound is evaluated for safety.
Investigational New Drug Application (IND).
After completing preclinical testing, a company
files an IND with the U.S. Food and Drug
8
Administration (FDA) to begin to test the drug
in people. The IND shows results of previous
experiments; how, where and by whom the
new studies will be conducted; the chemical
structure of the compound; how it is thought
to work in the body; any toxic effects found in
the animal studies; and how the compound
is manufactured. All clinical trials must be
reviewed and approved by the Institutional
Review Board (IRB) where the trials will be
conducted. Progress reports on clinical trials
must be submitted at least annually to FDA and
the IRB.
Clinical Trials, Phase I. These tests usually involve about 20 to 100 normal, healthy
volunteers. The tests study a drug’s safety
profile, including the safe dosage range. The
studies also determine how a drug is absorbed,
distributed, metabolized, and excreted as well
as the duration of its action.
Clinical Trials, Phase II. In this phase,
controlled trials of approximately 100 to 500
volunteer patients (people with the disease)
assess a drug’s effectiveness and determine
the early side effect profile.
Clinical Trials, Phase III. This phase usually
involves 1,000 to 5,000 patients in clinics and
hospitals. Physicians monitor patients closely to
confirm efficacy and identify adverse events.
New Drug Application (NDA)/Biologic
License Application (BLA). Following the
completion of all three phases of clinical trials,
a company analyzes all of the data and files an
NDA or BLA with FDA if the data successfully
demonstrate both safety and effectiveness.
The applications contain all of the scientific
information that the company has gathered.
Applications typically run 100,000 pages or
more. The average review time for the 21 new
therapeutics approved by the FDA in 2010 was
14.8 months.
Approval. Once FDA approves an NDA or
BLA, the new medicine becomes available
for physicians to prescribe. A company must
continue to submit periodic reports to FDA,
including any cases of adverse reactions and
appropriate quality-control records. For some
medicines, FDA requires additional trials
(Phase IV) to evaluate long-term effects.
Discovering and developing safe and effective
new medicines is a long, difficult, and expensive
process. Pharmaceutical companies invested an
estimated $67.4 billion in research and development in 2010.
PhRMA • PHARMACEUTICAL CLINICAL TRIALS IN GEORGIA
The Good News –
Many Clinical Trials are
Still Recruiting
There are nearly 400 clinical trials recruiting in Georgia. These trials target the top six chronic diseases and other
debilitating diseases affecting Americans and Georgians.
Location
Asthma
Cancer
Diabetes
Heart Disease
Mental Illness
Stroke
Albany
3
9
0
0
0
0
Athens
0
20
1
1
0
1
Atlanta
4
122
26
26
72
5
Augusta
0
41
3
6
4
5
Columbus
5
7
6
1
1
1
Decatur
0
6
14
5
8
4
Duluth
0
2
4
2
0
2
Gainesville
1
19
0
3
0
1
Lawrenceville
2
15
5
1
3
4
Macon
1
19
2
4
0
1
Marietta
2
37
5
1
8
1
Savannah
6
20
6
4
0
4
Source: www.clinicaltrials.gov
Note: Search criteria = Georgia, Phase I, II, II; industry only. Search performed 10/31/2011. See Appendix for detailed information about these clinical trials. Disease
columns will not add to totals in Appendix because some clinical trials are recruiting in more than one city.
DEVELOPING CURES, CREATING JOBS • A PARTNERSHIP BETWEEN BIOPHARMACEUTICAL COMPANIES AND STATE RESEARCH INSTITUTIONS
9
The Good News –
Many Clinical Trials are Still Recruiting
(continued)
Asthma – Leading Institutions Conducting
Clinical Trials
Aeroallergy Research Laboratories, Savannah
Allergy and Asthma Consultants PC Laboratory,
Lilburn
Atlanta Allergy & Asthma, Woodstock
Brookstone Centre Parkway, Columbus
DataQuest Medical Research, Lawrenceville
Georgia Pollens Clinical Research Centers, Albany
Cancer – Leading Institutions Conducting
Clinical Trials
Aflac Cancer Center and Blood Disorders,
Emory University, Atlanta
Atlanta Cancer Care, Atlanta
Atlanta’s Women’s Research Institute, Atlanta
Better Health Clinical Research, Newnan
Blood and Bone Marrow Transplant Group of
Georgia, Atlanta
Blood and Bone Marrow Transplant Program at
Northside Hospital, Atlanta
Cancer Center at DeKalb Medical, Decatur
Central Georgia Cancer Care, Macon
Children’s Healthcare of Atlanta at Emory
University, Atlanta
Children’s Hospital of Atlanta, Atlanta
Columbus Regional, Columbus
Dublin Hematology/Oncology, Dublin
Emory Clinical, Atlanta
Georgia Cancer Center, Atlanta
Georgia Cancer Specialists; Atlanta, Decatur, Macon,
Marietta, Sandy Springs
Georgia Health Sciences University, Augusta
10
John B. Amos Cancer Center, Columbus
Medical College of Georgia, Augusta
Memorial Health University Medical Center,
Savannah
Nancy N. and J.C. Lewis Cancer Center and
Research Pavilion at St. Joseph/Candler,
Savannah
Northeast Georgia Cancer Care, Athens
Northeast Georgia Medical Center, Gainesville
Northside Hospital, Atlanta
Northwest Georgia Oncology Centers, Austell,
Carrollton, Marietta
Peachtree Hematology-Oncology Consultants,
Atlanta
Phoebe Putney Memorial Hospital Cancer Center,
Albany
Piedmont Hospital Research Institute, Atlanta
SCRI Chattanooga Oncology & Hematology
Associates, Ringgold
South Coast Imaging Center, Savannah
Southeastern Gynecologic Oncology, Gainesville
Suburban Hematology-Oncology, Lawrenceville
Summit Cancer Care, Savannah
Wellstar Cancer Research, Marietta
Winship Cancer Institute at Emory University,
Atlanta
Diabetes – Leading Institutions Conducting
Clinical Trials
ACCR Nephrology Research, Atlanta
Atlanta Clinical Research Centers, Tucker
Atlanta Diabetes Associates, Atlanta
Atlanta Nephrology Referral Center, Decatur
Atlanta Pharmaceutical Research, Decatur
PhRMA • PHARMACEUTICAL CLINICAL TRIALS IN GEORGIA
Canton Kidney Center, Canton
Emory University, Atlanta
Endocrine Research Solutions, Roswell
In-Quest Medical Research, Duluth
Kaiser Permanente, Tucker
Kidney Care Associates, Augusta
Laureate Clinical Research Group, Atlanta
Meridian Research, Columbus
Middle Georgia Clinical Research Center, Perry
Mount Vernon Clinical Research, Sandy Springs
Renal Physicians of Georgia, Macon
Southern Clinical Research and Management,
Augusta
Heart Disease – Leading Institutions
Conducting Clinical Trials
Emory Clinic-Crawford Long Hospital, Atlanta
Emory University Hospital Midtown, Atlanta
Emory University Hospital, Atlanta
Medical Center of Georgia, Macon
Morehouse School of Medicine, Atlanta
Northeast Georgia Heart Center, Gainesville
Piedmont Heart Institute, Atlanta
South Coast Imaging Center, Savannah
St. Joseph’s Hospital of Atlanta, Atlanta
Mental Illness – Leading Institutions
Conducting Clinical Trials
Atlanta Center for Medical Research, Atlanta
Atlanta Institute of Medicine & Research, Atlanta
Atlanta VA Medical Center, Atlanta
Carman Research, Smyrna
Comprehensive NeuroScience, Atlanta
Emory University, Atlanta
Institute for Behavioral Medicine, Smyrna
Medical College of Georgia, Movements
Disorders Program, Augusta
Northwest Behavioral Research Center, Marietta,
Roswell
Sleep Disorders Center of Georgia, Atlanta
Stroke – Leading Institutions Conducting
Clinical Trials
Emory University, Atlanta
Georgia Health Sciences University, Augusta
Gwinnett Medical Center, Duluth
Memorial Health University Medical Center,
Savannah
Neuroscience Research Institute/
DeKalb Neurology, Lawrenceville
Shepherd Center, Atlanta
DEVELOPING CURES, CREATING JOBS • A PARTNERSHIP BETWEEN BIOPHARMACEUTICAL COMPANIES AND STATE RESEARCH INSTITUTIONS
11
Appendix
The clinical trials listed here involve tests that have not yet started recruiting patients or are just now
seeking volunteers to participate. This information is potentially valuable to patients still seeking effective
treatments for their chronic diseases. It provides a new therapeutic option to discuss with physicians.
Those interested in obtaining more information about certain trials can use the URL code listed for each
test to log onto www.clinicaltrials.gov, the clinical tests database of the National Institutes of Health.
Asthma
(13 clinical trials recruiting)
Study 1:
Safety of QMF149 Twisthaler® in Adolescent and
Adult Patients With Asthma
URL: http://ClinicalTrials.gov/show/NCT00941798
Study 2:
A Study to Evaluate the Efficacy and Safety of
Reslizumab (3.0 mg/kg) in the Reduction of Clinical
Asthma Exacerbations in Patients (12-75 Years of Age)
With Eosinophilic Asthma
URL: http://ClinicalTrials.gov/show/NCT01285323
Study 3:
A Study of the Bronchodilator Effect of Formoterol
Fumarate Used in Combination With Mometasone
Furoate Metered Dose Inhaler in Children With
Persistent Asthma (P06476 AM2)(MK-0887A-178-0)
URL: http://ClinicalTrials.gov/show/NCT01258803
Study 4:
A Study to Evaluate the Efficacy and Safety of
Reslizumab (0.3 or 3.0 mg/kg) as Treatment for
Patients (12-75 Years of Age) With Eosinophilic Asthma
URL: http://ClinicalTrials.gov/show/NCT01270464
Study 5:
Epinephrine Inhalation Aerosol USP: For Evaluation
Of Efficacy And Safety In Asthma Patients
URL: http://ClinicalTrials.gov/show/NCT01357642
Study 6:
A Safety, Efficacy and Tolerability Study in Pediatric
Subjects With Asthma
URL: http://ClinicalTrials.gov/show/NCT00809757
Study 7:
Study to Evaluate the Efficacy and Safety of MEDI-563
in Adults With Uncontrolled Asthma
URL: http://ClinicalTrials.gov/show/NCT01238861
Study 8:
A 6-week Study in Asthmatic Children Aged 6 to <12
Yrs Comparing Budesonide pMDI 160ug Twice Daily
With Placebo
URL: http://ClinicalTrials.gov/show/NCT01136382
12
PhRMA • PHARMACEUTICAL CLINICAL TRIALS IN GEORGIA
Study 9:
A Phase 2b, Randomized, Double-blind Study to
Evaluate the Efficacy of Tralokinumab in Adults With
Asthma
URL: http://ClinicalTrials.gov/show/NCT01402986
Study 10:
Evaluating the Efficacy and Safety of Fluticasone
Furoate in the Treatment of Asthma in Adults and
Adolescents
URL: http://ClinicalTrials.gov/show/NCT01431950
Study 11:
Efficacy, Safety, and Pharmacokinetics of QAW039
URL: http://ClinicalTrials.gov/show/NCT01253603
Study 12:
Efficacy and Safety of Budesonide Foam for Patients
With Active Mild to Moderate Ulcerative Proctitis or
Proctosigmoiditis
URL: http://ClinicalTrials.gov/show/NCT01008410
Study 13:
Efficacy and Safety of Budesonide Foam for Patients
With Active Mild to Moderate Ulcerative Proctitis or
Proctosigmoiditis
URL: http://ClinicalTrials.gov/show/NCT01008423
Cancer
(200 clinical trials recruiting)
Study 1:
PEAK: A Phase 2 Study of Panitumumab Plus
mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for
First Line Treatment of Metastatic Colorectal Cancer
Subjects With Wild-Type KRAS Tumors
URL: http://ClinicalTrials.gov/show/NCT00819780
Study 2:
GSK1572932A Antigen-Specific Cancer
Immunotherapeutic as Adjuvant Therapy in Patients
With Non-Small Cell Lung Cancer
URL: http://ClinicalTrials.gov/show/NCT00480025
Study 3:
A Study in Ovarian, Non-Small Cell Lung, Prostate,
Colorectal, Gastroesophageal Cancers, and Squamous
Cell Carcinoma of the Head and Neck
URL: http://ClinicalTrials.gov/show/NCT01059643
Study 4:
Anemia Treatment for Advanced Non-Small Cell Lung
Cancer (NSCLC) Patients Receiving Chemotherapy
URL: http://ClinicalTrials.gov/show/NCT00858364
Study 5:
A Study in Second Line Non Small Cell Lung Cancer
URL: http://ClinicalTrials.gov/show/NCT01168973
Study 6:
Trial of Gemcitabine/Carboplatin With or Without
Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects
With Previously Untreated Stage IV Squamous
Non-Small-Cell Lung Cancer (NSCLC)
URL: http://ClinicalTrials.gov/show/NCT01082549
Study 7:
ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib
for the Treatment of Non-squamous, Non-small-cell
Lung Cancer
URL: http://ClinicalTrials.gov/show/NCT01244191
Study 8:
A Study for Patients With Pancreatic Cancer
URL: http://ClinicalTrials.gov/show/NCT00839332
Study 9:
Continued HER2 Suppression With Lapatinib Plus
Trastuzumab Versus Trastuzumab Alone
URL: http://ClinicalTrials.gov/show/NCT00968968
Study 10:
A Study of Pertuzumab in Addition to Chemotherapy
and Herceptin (Trastuzumab) as Adjuvant Therapy in
Patients With HER2-Positive Primary Breast Cancer
URL: http://ClinicalTrials.gov/show/NCT01358877
Study 11:
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks
vs. Every 12 Weeks) in Patients With Documented Bone
Metastases From Bone Cancer
URL: http://ClinicalTrials.gov/show/NCT00320710
DEVELOPING CURES, CREATING JOBS • A PARTNERSHIP BETWEEN BIOPHARMACEUTICAL COMPANIES AND STATE RESEARCH INSTITUTIONS
13
Study 12:
A Study of Trastuzumab-Emtasine (T-DM1) Plus
Pertuzumab/Pertuzumab Placebo Versus Trastuzumab
[Herceptin] Plus a Taxane in Patients With Metastatic
Breast Cancer (MARIANNE)
URL: http://ClinicalTrials.gov/show/NCT01120184
Study 13:
An Open-Label Study of Trastuzumab-MCC-DM1
(T-DM1) vs Capecitabine+Lapatinib in Patients With
HER2-Positive Locally Advanced or Metastatic Breast
Cancer (EMILIA)
URL: http://ClinicalTrials.gov/show/NCT00829166
Study 14:
A Study of ALT-801 in Combination With Cisplatin
and Gemcitabine in Muscle Invasive or Metastatic
Urothelial Cancer
URL: http://ClinicalTrials.gov/show/NCT01326871
Study 15:
Phase III Study of Docetaxel + Ramucirumab or
Placebo in Breast Cancer
URL: http://ClinicalTrials.gov/show/NCT00703326
Study 16:
A Study in Second Line Metastatic Colorectal Cancer
URL: http://ClinicalTrials.gov/show/NCT01183780
Study 17:
Trial of Gemcitabine With or Without Bavituximab in
Patients With Previously Untreated Stage IV Pancreatic
Cancer
URL: http://ClinicalTrials.gov/show/NCT01272791
Study 18:
Study Evaluating The Effects Of Neratinib After
Adjuvant Trastuzumab In Women With Early Stage
Breast Cancer
URL: http://ClinicalTrials.gov/show/NCT00878709
Study 19:
Study for Women With Platinum Resistant Ovarian
Cancer Evaluating EC145 in Combination With Doxil®
(PROCEED)
URL: http://ClinicalTrials.gov/show/NCT01170650
14
Study 20:
Efficacy and Safety of MORAb-003 in Subjects With
Platinum-sensitive Ovarian Cancer in First Relapse
URL: http://ClinicalTrials.gov/show/NCT00849667
Study 21:
A Study of CDX-011 (CR011-vcMMAE) in Patients
With Advanced GPNMB-expressing Breast Cancer
URL: http://ClinicalTrials.gov/show/NCT01156753
Study 22:
Imetelstat in Combination With Paclitaxel (With or
Without Bevacizumab) in Patients With Locally
Recurrent or Metastatic Breast Cancer
URL: http://ClinicalTrials.gov/show/NCT01256762
Study 23:
Sativex® for Relieving Persistent Pain in Patients
With Advanced Cancer
URL: http://ClinicalTrials.gov/show/NCT01361607
Study 24:
Study of Ganetespib (STA-9090) + Docetaxel in
Advanced Non Small Cell Lung Cancer
URL: http://ClinicalTrials.gov/show/NCT01348126
Study 25:
Eribulin With Trastuzumab as First-line Therapy
for Locally Recurrent or Metastatic HER2 Positive
Breast Cancer
URL: http://ClinicalTrials.gov/show/NCT01269346
Study 26:
Study of IMC-18F1 or Ramucirumab DP in
Combination With Capecitabine or Capecitabine
on Previously Treated Breast Cancer Patients
URL: http://ClinicalTrials.gov/show/NCT01234402
Study 27:
A Study for Patients With Small-Cell Lung Cancer
URL: http://ClinicalTrials.gov/show/NCT01025284
Study 28:
Phase 3 Study of Immunotherapy to Treat Advanced
Prostate Cancer
URL: http://ClinicalTrials.gov/show/NCT01057810
PhRMA • PHARMACEUTICAL CLINICAL TRIALS IN GEORGIA
Study 29:
A Study of Tasquinimod in Men With Metastatic
Castrate Resistant Prostate Cancer
URL: http://ClinicalTrials.gov/show/NCT01234311
Study 30:
A Study of Pemetrexed, Carboplatin and Bevacizumab
in Patients With Nonsquamous Non-Small Cell Lung
Cancer
URL: http://ClinicalTrials.gov/show/NCT00762034
Study 31:
Chemotherapy and Radiation in Treating Patients
With Stage 3 Non-Small Cell Lung Cancer
URL: http://ClinicalTrials.gov/show/NCT00686959
Study 32:
Effect of GTx-758 on Total and Free Testosterone
Levels in Men With Prostate Cancer
URL: http://ClinicalTrials.gov/show/NCT01326312
Study 33:
Safety and Efficacy of BKM120 in Patients With
Metastatic Non-small Cell Lung Cancer
URL: http://ClinicalTrials.gov/show/NCT01297491
Study 34:
Study of Patients With Advanced Non-Small Cell
Lung Cancer
URL: http://ClinicalTrials.gov/show/NCT00948675
Study 35:
A Study of Single-Agent Eribulin Mesylate as
First-Line Therapy for Locally Recurrent or
Metastatic Human Epidermal Growth Factor
Receptor Two (HER2) Negative Breast Cancer
URL: http://ClinicalTrials.gov/show/NCT01268150
Study 36:
Continuation Study of Lapatinib Monotherapy or
Lapatinib in Combination With Other Anti-cancer Agents
URL: http://ClinicalTrials.gov/show/NCT00790816
Study 37:
Comparison of Docetaxel/Prednisone to Docetaxel/
Prednisone in Combination With OGX-011 in Men
With Prostate Cancer
URL: http://ClinicalTrials.gov/show/NCT01188187
Study 38:
A Clinical Trial Testing The Efficacy Of Crizotinib
Versus Standard Chemotherapy Pemetrexed Plus
Cisplatin Or Carboplatin In Patients With ALK
Positive Non Squamous Cancer Of The Lung
URL: http://ClinicalTrials.gov/show/NCT01154140
Study 39:
Daily Everolimus in Combination With Trastuzumab
and Vinorelbine in HER2/Neu Positive Women With
Locally Advanced or Metastatic Breast Cancer
URL: http://ClinicalTrials.gov/show/NCT01007942
Study 40:
Study of Denosumab as Adjuvant Treatment for
Women With High Risk Early Breast Cancer Receiving
Neoadjuvant or Adjuvant Therapy (D-CARE)
URL: http://ClinicalTrials.gov/show/NCT01077154
Study 41:
Study of MEDI-573 Plus Standard Endocrine Therapy
for Women With Hormone-sensitive Metastatic Breast
Cancer
URL: http://ClinicalTrials.gov/show/NCT01446159
Study 42:
A Study in Cancer Patients to Evaluate the
Bioequivalence of Alternative Formulations of
Lapatinib
URL: http://ClinicalTrials.gov/show/NCT00996762
Study 43:
Phase III Trial Comparing Capecitabine in
Combination With Sorafenib or Placebo in the
Treatment of Locally Advanced or Metastatic
HER2-Negative Breast Cancer
URL: http://ClinicalTrials.gov/show/NCT01234337
Study 44:
Study of Erlotinib With or Without Investigational
Drug (U3-1287) in Subjects With Advanced Non-small
Cell Lung Cancer
URL: http://ClinicalTrials.gov/show/NCT01211483
Study 45:
A Study of Ramucirumab in Patients With Gastric,
Esophageal and Gastroesophageal Cancer
URL: http://ClinicalTrials.gov/show/NCT01246960
DEVELOPING CURES, CREATING JOBS • A PARTNERSHIP BETWEEN BIOPHARMACEUTICAL COMPANIES AND STATE RESEARCH INSTITUTIONS
15
Study 46:
Eribulin in Combination With Capecitabine for
Adjuvant Treatment in Estrogen Receptor-Positive
Early Stage Breast Cancer
URL: http://ClinicalTrials.gov/show/NCT01439282
Study 47:
A Study of MDV3100 Versus Bicalutamide in Castrate
Men With Metastatic Prostate Cancer
URL: http://ClinicalTrials.gov/show/NCT01288911
Study 48:
A Phase I Study of ABT-888 in Combination With
Conventional Whole Brain Radiation Therapy (WBRT)
in Cancer Patients
URL: http://ClinicalTrials.gov/show/NCT00649207
Study 49:
A Study in Head and Neck Cancer
URL: http://ClinicalTrials.gov/show/NCT01081041
Study 50:
Study of Carboplatin/Paclitaxel in Combination With
ABT-869 in Subjects With Advanced or Metastatic
Non-Small Cell Lung Cancer (NSCLC)
URL: http://ClinicalTrials.gov/show/NCT00716534
Study 51:
A Study of Trastuzumab Emtansine in Comparison
With Treatment of Physician’s Choice in Patients
With HER2-Positive Breast Cancer Who Have
Received at Least Two Prior Regimens of
HER2-Directed Therapy
URL: http://ClinicalTrials.gov/show/NCT01419197
Study 52:
An Efficacy and Safety Study of MORAb-003
in Platinum-Resistant or Refractory Relapsed
Ovarian Cancer
URL: http://ClinicalTrials.gov/show/NCT00738699
Study 53:
Dasatinib Added to Gemcitabine for Subjects With
Locally-advanced Pancreatic Cancer
URL: http://ClinicalTrials.gov/show/NCT01395017
16
Study 54:
A Study of the HSP90 Inhibitor, STA-9090 in Subjects
With Stage IIIB or IV Non-Small Cell Lung Cancer
(NSCLC)
URL: http://ClinicalTrials.gov/show/NCT01031225
Study 55:
IMAAGEN: Impact of Abiraterone Acetate in
Prostate-Specific Antigen
URL: http://ClinicalTrials.gov/show/NCT01314118
Study 56:
Prediction of Response to Neoadjuvant Chemotherapy
in Women With Operable Breast Cancer
URL: http://ClinicalTrials.gov/show/NCT01007890
Study 57:
ErbB2 Over-Expressing Metastatic Breast Cancer
Study Using Paclitaxel, Trastuzumab, and Lapatinib
URL: http://ClinicalTrials.gov/show/NCT00272987
Study 58:
Long Term Safety of Sativex® Oromucosal Spray
(Sativex®; Nabiximols) as Adjunctive Therapy in
Patients With Uncontrolled Persistent Chronic
Cancer Related Pain
URL: http://ClinicalTrials.gov/show/NCT01337089
Study 59:
A Study of Ramucirumab (IMC-1121B) in
Combination With Eribulin Versus Eribulin Alone
in Patients With Breast Cancer
URL: http://ClinicalTrials.gov/show/NCT01427933
Study 60:
A Dose Escalation Study of STA-9090 and Docetaxel
in Patients With Solid Tumors
URL: http://ClinicalTrials.gov/show/NCT01183364
Study 61:
Study of Immunotherapy to Treat Advanced Prostate
Cancer
URL: http://ClinicalTrials.gov/show/NCT00861614
PhRMA • PHARMACEUTICAL CLINICAL TRIALS IN GEORGIA
Study 62:
A Study of Ixabepilone as Second Line Therapy
for Locally Advanced, Recurrent or Metastatic
Endometrial Cancer
URL: http://ClinicalTrials.gov/show/NCT00883116
Study 63:
Study of Cabozantinib (XL184) in Adults With
Advanced Malignancies
URL: http://ClinicalTrials.gov/show/NCT00940225
Study 64:
A Study of Avastin (Bevacizumab) in Combination
With Standard of Care Treatment in Patients With
Lung Cancer
URL: http://ClinicalTrials.gov/show/NCT01351415
Study 65:
A Study of ALT-836 in Combination With Gemcitabine
for Locally Advanced or Metastatic Solid Tumors
URL: http://ClinicalTrials.gov/show/NCT01325558
Study 66:
Study Evaluating the Safety and Efficacy of
MEGF0444A in Combination With Carboplatin,
Paclitaxel and Bevacizumab in Patients With Advanced
or Recurrent Non-Squamous Non-Small Cell Lung
Cancer Who Have Not Received Prior Chemotherapy
for Advanced Disease (NILE)
URL: http://ClinicalTrials.gov/show/NCT01366131
Study 67:
A Study for Patients With Recurrent or Metastatic
Squamous Cell Head and Neck Cancer
URL: http://ClinicalTrials.gov/show/NCT01087970
Study 68:
Study of GDC-0941 or GDC-0980 With Fulvestrant
Versus Fulvestrant in Advanced or Metastatic Breast
Cancer in Patients Resistant to Aromatase Inhibitor
Therapy
URL: http://ClinicalTrials.gov/show/NCT01437566
Study 69:
Study of BMS-754807 Combined With Letrozole
or BMS-754807 Alone in Patients With Hormone
Receptor-Positive Breast Cancer and Resistance
to Non-Steroidal Aromatase Inhibitors
URL: http://ClinicalTrials.gov/show/NCT01225172
Study 70:
An Open-label Study of GSK1120212 Compared With
Docetaxel in Stage IIIb-IV KRAS-mutant Non-small
Cell Lung Cancer
URL: http://ClinicalTrials.gov/show/NCT01362296
Study 71:
ARCHER 1009 : A Phase 3 Study Of PF-00299804,
A Pan-HER Inhibitor, Vs. Erlotinib In The Treatment
Of Advanced Non-Small Cell Lung Cancer
URL: http://ClinicalTrials.gov/show/NCT01360554
Study 72:
Phase 1 Study of CEP-37250/KHK2804 in Subjects
With Advanced Solid Tumors
URL: http://ClinicalTrials.gov/show/NCT01447732
Study 73:
NP2 Enkephalin For Treatment of Intractable
Cancer Pain
URL: http://ClinicalTrials.gov/show/NCT01291901
Study 74:
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of
Liver Metastasis From Colon Cancer With Systemic
FOLFOX6
URL: http://ClinicalTrials.gov/show/NCT00932438
Study 75:
Efficacy and Safety of Masitinib (AB1010) in
Comparison to Imatinib in Patients With
Gastro-intestinal Stromal Tumour
URL: http://ClinicalTrials.gov/show/NCT00812240
Study 76:
Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd
Line Metastatic Breast Cancer
URL: http://ClinicalTrials.gov/show/NCT00924352
Study 77:
Phase III Study of ABI-007(Albumin-bound Paclitaxel)
Plus Gemcitabine Versus Gemcitabine in Metastatic
Adenocarcinoma of the Pancreas
URL: http://ClinicalTrials.gov/show/NCT00844649
Study 78:
Re-expression of ER in Triple Negative Breast Cancers
URL: http://ClinicalTrials.gov/show/NCT01194908
DEVELOPING CURES, CREATING JOBS • A PARTNERSHIP BETWEEN BIOPHARMACEUTICAL COMPANIES AND STATE RESEARCH INSTITUTIONS
17
Study 79:
A Clinical Trial Comparing the Combination of TC
Plus Bevacizumab to TC Alone and to TAC for Women
With Node-Positive or High-Risk Node-Negative,
HER2-Negative Breast Cancer
URL: http://ClinicalTrials.gov/show/NCT00887536
Study 80:
Chemotherapy and Lapatinib or Trastuzumab in
Treating Women With HER2/Neu-Positive Metastatic
Breast Cancer
URL: http://ClinicalTrials.gov/show/NCT00667251
Study 81:
A Study to Evaluate the Safety and Efficacy of
Inactivated Varicella-zoster Vaccine (VZV) as a
Preventative Treatment for Herpes Zoster (HZ) and
HZ-related Complications in Adult Participants With
Solid Tumor or Hematologic Malignancy (V212-011)
URL: http://ClinicalTrials.gov/show/NCT01254630
Study 82:
An Assessment of an Attenuated Live Listeria Vaccine
in CIN 2+
URL: http://ClinicalTrials.gov/show/NCT01116245
Study 83:
Preoperative Pemetrexed and Carboplatin for Select
Stage IB, II, and III Non-Squamous Non-Small-Cell
Lung Cancer
URL: http://ClinicalTrials.gov/show/NCT00906282
Study 84:
A Study of Carboplatin, Cetuximab and RAD001 in
Advanced Head and Neck Cancer
URL: http://ClinicalTrials.gov/show/NCT01283334
Study 85:
Trial Using Docetaxel Cytoxan in Breast Cancers With
High Recurrence Scores
URL: http://ClinicalTrials.gov/show/NCT00832338
Study 86:
LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive
Metastatic Breast Cancer Patients After One Prior
Herceptin Treatment
URL: http://ClinicalTrials.gov/show/NCT01125566
18
Study 87:
A Study to Compare the Safety and Efficacy of an
Aromatase Inhibitor in Combination With Lapatinib,
Trastuzumab or Both for the Treatment of Hormone
Receptor Positive, HER2+ Metastatic Breast Cancer
URL: http://ClinicalTrials.gov/show/NCT01160211
Study 88:
Neoadjuvant Sunitinib With Paclitaxel/Carboplatin
in Patients With Triple-Negative Breast Cancer
URL: http://ClinicalTrials.gov/show/NCT00887575
Study 89:
Trial of Amrubicin as Treatment for Patients With
HER2-Negative Metastatic Breast Cancer
URL: http://ClinicalTrials.gov/show/NCT01033032
Study 90:
Safety and Efficacy Study of Gemcitabine Plus
Bevacizumab in Patients With Platinum-Resistant
Ovarian, Primary Peritoneal or Fallopian Tube Cancer
URL: http://ClinicalTrials.gov/show/NCT01131039
Study 91:
Carboplatin, Pemetrexed, and Panitumumab in Patients
With Advanced Non-Squamous K-ras Wild Type NSCLC
URL: http://ClinicalTrials.gov/show/NCT01042288
Study 92:
A Study of Paclitaxel With or Without Ramucirumab
in Metastatic Gastric Adenocarcinoma
URL: http://ClinicalTrials.gov/show/NCT01170663
Study 93:
Trastuzumab With or Without Everolimus in Estrogen
Receptor-Positive Metastatic Breast Cancer
URL: http://ClinicalTrials.gov/show/NCT00912340
Study 94:
Preoperative Clinical Trial of Sorafenib in Combination
With Cisplatin Followed by Paclitaxel for Triple
Negative (ER-, PR-, Her2-)Early Stage Breast Cancer
URL: http://ClinicalTrials.gov/show/NCT01194869
Study 95:
A Study to Evaluate Pazopanib as an Adjuvant
Treatment for Localized Renal Cell Carcinoma (RCC)
URL: http://ClinicalTrials.gov/show/NCT01235962
PhRMA • PHARMACEUTICAL CLINICAL TRIALS IN GEORGIA
Study 96:
FOLFOXIRI Plus Panitumumab Patients With
Metastatic KRAS Wild-Type Colorectal Cancer With
Liver Metastases Only
URL: http://ClinicalTrials.gov/show/NCT01226719
Study 97:
A Phase II Trial of OSI-906 and Sorafenib in Advanced
Hepatocellular Cancer
URL: http://ClinicalTrials.gov/show/NCT01334710
Study 98:
Paclitaxel and Carboplatin With Or Without Sorafenib
In The First-Line Treatment Of Patients With Ovarian
Cancer
URL: http://ClinicalTrials.gov/show/NCT00390611
Study 99:
A Trial of Pasireotide and Everolimus in Adult Patients
With Radioiodine-Refractory Differentiated and
Medullary Thyroid Cancer
URL: http://ClinicalTrials.gov/show/NCT01270321
Study 100:
High-dose Bevacizumab in Advanced Renal Carcinoma
Patients
URL: http://ClinicalTrials.gov/show/NCT00455975
Study 101:
Study of MLN4924 in Adult Patients With
Nonhematologic Malignancies
URL: http://ClinicalTrials.gov/show/NCT00677170
Study 102:
Phase II Study of Cabazitaxel-XRP6258 in Advanced
Non-Small Cell Lung Cancer
URL: http://ClinicalTrials.gov/show/NCT01438307
Study 103:
A Phase 1 Study of MLN9708 in Adult Patients With
Advanced Nonhematologic Malignancies
URL: http://ClinicalTrials.gov/show/NCT00830869
Study 104:
Phase 2 Study of Maintenance OSI-906 Plus Erlotinib
(Tarceva®), or Placebo Plus Erlotinib in Patients With
Nonprogression Following 4 Cycles of Platinum-based
Chemotherapy
URL: http://ClinicalTrials.gov/show/NCT01186861
Study 105:
Phase I Chemoprevention Trial With Green Tea
Polyphenon E and Erlotinib in Patients With
Premalignant Lesions of the Head and Neck
URL: http://ClinicalTrials.gov/show/NCT01116336
Study 106:
Exemestane or Docetaxel-cytoxan in Low Recurrence
Score Cancers
URL: http://ClinicalTrials.gov/show/NCT00941330
Study 107:
Trial of Poor Performance Status Patients (ToPPS)
URL: http://ClinicalTrials.gov/show/NCT00892710
Study 108:
A Phase 2, Open-Label Study of Amuvatinib in
Combination With Platinum-Etoposide Chemotherapy
in Small Cell Lung Cancer
URL: http://ClinicalTrials.gov/show/NCT01357395
Study 109:
Efficacy/Safety of Imprime PGG® Injection With
Cetuximab and Paclitaxel/Carboplatin Therapy in
Patients With Untreated Advanced Non-Small Cell
Lung Cancer (NSCLC)
URL: http://ClinicalTrials.gov/show/NCT00874848
Study 110:
Study of MLN4924, a Novel Inhibitor of Nedd8
Activating Enzyme, in Adult Patients With Lymphoma
or Multiple Myeloma
URL: http://ClinicalTrials.gov/show/NCT00722488
Study 111:
A Dose-Escalation and Pharmacokinetic Study of
TG02 Citrate in Patients With Advanced Hematological
Malignancies
URL: http://ClinicalTrials.gov/show/NCT01204164
Study 112:
Study of Everolimus (RAD001)in Combination With
Lenalidomide
URL: http://ClinicalTrials.gov/show/NCT01218555
Study 113:
A Study in Non-Small Cell Lung Cancer
URL: http://ClinicalTrials.gov/show/NCT01232452
DEVELOPING CURES, CREATING JOBS • A PARTNERSHIP BETWEEN BIOPHARMACEUTICAL COMPANIES AND STATE RESEARCH INSTITUTIONS
19
Study 114:
Study of Modified Docetaxel, Cisplatin, and
Fluorouracil (mDCF) in Unresectable or Metastatic
Gastric and Gastroesophageal Junction
Adenocarcinoma
URL: http://ClinicalTrials.gov/show/NCT00515411
Study 115:
ABT-348 as Monotherapy to Treat Advanced
Hematologic Malignancies
URL: http://ClinicalTrials.gov/show/NCT01110473
Study 116:
Multiple Ascending Dose (MDX1105-01)
URL: http://ClinicalTrials.gov/show/NCT00729664
Study 117:
Ramucirumab or Anti-PDGFR Alpha Monoclonal
Antibody IMC-3G3 in Treating Patients With Recurrent
Glioblastoma Multiforme
URL: http://ClinicalTrials.gov/show/NCT00895180
Study 118:
Phase 1 and 2 Study of PX-866 and Cetuximab
URL: http://ClinicalTrials.gov/show/NCT01252628
Study 119:
Assessment of Efficacy and Safety in Relieving
Opioid-induced Constipation in Patients With
Cancer-related Pain
URL: http://ClinicalTrials.gov/show/NCT01384292
Study 120:
A Study Of Panobinostat In Children With Refractory
Hematologic Malignancies
URL: http://ClinicalTrials.gov/show/NCT01321346
Study 121:
A Study of Sativex® for Relieving Persistent Pain in
Patients With Advanced Cancer
URL: http://ClinicalTrials.gov/show/NCT01262651
Study 122:
Efficacy Study of REOLYSIN® in Combination With
Paclitaxel and Carboplatin in Platinum-Refractory
Head and Neck Cancers
URL: http://ClinicalTrials.gov/show/NCT01166542
20
Study 123:
Study to Evaluate Efficacy of CO-1.01 as Second Line
Therapy for Gemcitabine-Refractory Stage IV
Pancreatic Adenocarcinoma
URL: http://ClinicalTrials.gov/show/NCT01233375
Study 124:
CEP-18770 in Combination With Lenalidomide and
Dexamethasone in Relapsed or Refractory Multiple
Myeloma
URL: http://ClinicalTrials.gov/show/NCT01348919
Study 125:
A Study of the Safety and Efficacy of ONO-7746 in
Adult Cancer Patients With Chemotherapy Induced
Thrombocytopenia
URL: http://ClinicalTrials.gov/show/NCT01345214
Study 126:
Safety and Efficacy Study for Solid Tumor Patients
Treated With Eltrombopag
URL: http://ClinicalTrials.gov/show/NCT01147809
Study 127:
Treatment of Blood Clots in Children With Cancer
URL: http://ClinicalTrials.gov/show/NCT00952380
Study 128:
F18PET/CT Versus TC-MDP Scanning to Detect
Bone Mets
URL: http://ClinicalTrials.gov/show/NCT00882609
Study 129:
A Dose Finding and Safety Study of Oral LDE225 in
Children
URL: http://ClinicalTrials.gov/show/NCT01125800
Study 130:
A Study of LY2510924 and Sunitinib in Patients With
Metastatic Renal Cell Carcinoma
URL: http://ClinicalTrials.gov/show/NCT01391130
Study 131:
Study of ALT-801 With Cisplatin in Patients With
Metastatic Melanoma
URL: http://ClinicalTrials.gov/show/NCT01029873
PhRMA • PHARMACEUTICAL CLINICAL TRIALS IN GEORGIA
Study 132:
Panobinostat or Placebo With Bortezomib and
Dexamethasone in Patients With Relapsed Multiple
Myeloma
URL: http://ClinicalTrials.gov/show/NCT01023308
Study 133:
Safety and Dose Determining Multi-dose Study of
BT062 in Patients With Relapsed or Refractory
Multiple Myeloma
URL: http://ClinicalTrials.gov/show/NCT01001442
Study 134:
A Study of ARRY-520 in Patients With Relapsed or
Refractory Multiple Myeloma
URL: http://ClinicalTrials.gov/show/NCT00821249
Study 135:
Study of ACY-1215 Alone and in Combination With
Bortezomib and Dexamethasone in Multiple Myeloma
URL: http://ClinicalTrials.gov/show/NCT01323751
Study 136:
A Study of MLN9708 Administered in Combination
With Lenalidomide and Low-Dose Dexamethasone in
Patients With Newly Diagnosed Multiple Myeloma
URL: http://ClinicalTrials.gov/show/NCT01217957
Study 137:
A Study of hLL1-DOX (Milatuzumab-Doxorubicin
Antibody-Drug Conjugate) in Patients With Multiple
Myeloma
URL: http://ClinicalTrials.gov/show/NCT01101594
Study 138:
Study of Oral MLN9708 in Adult Patients With
Relapsed and Refractory Multiple Myeloma
URL: http://ClinicalTrials.gov/show/NCT00932698
Study 139:
Acceleration of Platelet Recovery Following
Autologous Peripheral Blood Stem Cell Transplant
(PBSC) in Hodgkin, Non-Hodgkin Lymphoma or
Multiple Myeloma Patients
URL: http://ClinicalTrials.gov/show/NCT01121120
Study 140:
Trial of an Intratumoral Injections of INXN-3001 in
Subjects With Stage III or IV Melanoma
URL: http://ClinicalTrials.gov/show/NCT00815607
Study 141:
Treatment Based on Molecular Profiling Diagnosis
Carcinoma of Unknown Primary Site
URL: http://ClinicalTrials.gov/show/NCT00737243
Study 142:
A Study of ARRY-520 and Bortezomib Plus
Dexamethasone in Patients With Relapsed/Refractory
Multiple Myeloma
URL: http://ClinicalTrials.gov/show/NCT01248923
Study 143:
Phase 1 Clinical Trial of NPI-0052 in Patients With
Relapsed or Relapsed/Refractory Multiple Myeloma
URL: http://ClinicalTrials.gov/show/NCT00461045
Study 144:
A Study of the Safety and Pharmacokinetics of
MFGR1877S in Patients With Relapsed or Refractory
t(4;14)-Positive Multiple Myeloma
URL: http://ClinicalTrials.gov/show/NCT01122875
Study 145:
Study of BHQ880 in Patients With High Risk
Smoldering Multiple Myeloma
URL: http://ClinicalTrials.gov/show/NCT01302886
Study 146:
Phase 3, Randomized, Open Label Trial of
Lenalidomide/Dexamethasone With or Without
Elotuzumab in Relapsed or Refractory Multiple
Myeloma
URL: http://ClinicalTrials.gov/show/NCT01239797
Study 147:
Phase III Study of Lenalidomide and Dexamethasone
With or Without Elotuzumab to Treat Newly
Diagnosed, Previously Untreated Multiple Myeloma
URL: http://ClinicalTrials.gov/show/NCT01335399
DEVELOPING CURES, CREATING JOBS • A PARTNERSHIP BETWEEN BIOPHARMACEUTICAL COMPANIES AND STATE RESEARCH INSTITUTIONS
21
Study 148:
Study of Vosaroxin or Placebo in Combination With
Cytarabine in Patients With First Relapsed or
Refractory Acute Myeloid Leukemia (AML)
URL: http://ClinicalTrials.gov/show/NCT01191801
Study 149:
Randomized Trial of Lenalidomide, Bortezomib,
Dexamethasone vs High-Dose Treatment With SCT
in MM Patients up to Age 65
URL: http://ClinicalTrials.gov/show/NCT01208662
Study 150:
A Study of the Combination Vorinostat With
Lenalidomide, Bortezomib and Dexamethasone for
Patients With Newly Diagnosed Multiple Myeloma
URL: http://ClinicalTrials.gov/show/NCT01038388
Study 151:
Clofarabine With Cytarabine for Patients With
Minimal Residual Disease Positive Leukemia
URL: http://ClinicalTrials.gov/show/NCT01158885
Study 152:
Safety Study of Lenalidomide Maintenance Therapy
Post Allogeneic HCT for High-risk Multiple Myeloma
URL: http://ClinicalTrials.gov/show/NCT00847639
Study 153:
Evaluation of the Drug Plerixafor in Combination With
Chemotherapy and G-CSF for Stem Cell Collection
URL: http://ClinicalTrials.gov/show/NCT01095757
Study 154:
A Study to Evaluate the Safety and Efficacy of
Ustekinumab in Patients With Moderately to Severely
Active Crohn’s Disease Who Have Failed or Are
Intolerant to Tumor Necrosis Factor (TNF) Antagonist
Therapy (UNITI-1)
URL: http://ClinicalTrials.gov/show/NCT01369329
Study 155:
A Study of Trabectedin or Dacarbazine for the
Treatment of Patients With Advanced L-sarcoma
URL: http://ClinicalTrials.gov/show/NCT01343277
22
Study 156:
Study of the Poly (ADP-ribose) Polymerase-1
(PARP-1) Inhibitor BSI-201 in Patients With Newly
Diagnosed Malignant Glioma
URL: http://ClinicalTrials.gov/show/NCT00687765
Study 157:
Erlotinib Versus Oral Etoposide in Patients With
Recurrent or Refractory Pediatric Ependymoma
URL: http://ClinicalTrials.gov/show/NCT01032070
Study 158:
Study of MDX-1203 in Subjects With Advanced/
Recurrent Clear Cell Renal Cell Carcinoma (ccRCC)
or Relapsed/Refractory B-Cell Non-Hodgkin’s
Lymphoma (B-NHL)
URL: http://ClinicalTrials.gov/show/NCT00944905
Study 159:
A Study of Ramucirumab (IMC-1121B) Drug Product
(DP) and Best Supportive Care (BSC) Versus Placebo
and BSC as 2nd-Line Treatment in Patients With
Hepatocellular Carcinoma After 1st-Line Therapy
With Sorafenib
URL: http://ClinicalTrials.gov/show/NCT01140347
Study 160:
A Study to Evaluate RAF265, an Oral Drug
Administered to Subjects With Locally Advanced or
Metastatic Melanoma
URL: http://ClinicalTrials.gov/show/NCT00304525
Study 161:
Study of Palifosfamide-tris in Combination With
Doxorubicin in Patients With Front-line Metastatic
Soft Tissue Sarcoma
URL: http://ClinicalTrials.gov/show/NCT01168791
Study 162:
A Study Evaluating the Efficacy and Safety of
GDC-0449 in Operable Basal Cell Carcinoma (BCC)
URL: http://ClinicalTrials.gov/show/NCT01201915
Study 163:
Efficacy and Safety of Midostaurin in Patients With
Aggressive Systemic Mastocytosis or Mast Cell
Leukemia
URL: http://ClinicalTrials.gov/show/NCT00782067
PhRMA • PHARMACEUTICAL CLINICAL TRIALS IN GEORGIA
Study 164:
Study to Demonstrate the Efficacy and Safety of
Propranolol Oral Solution in Infants With
Proliferating Infantile Hemangiomas Requiring
Systemic Therapy
URL: http://ClinicalTrials.gov/show/NCT01056341
Study 165:
Ph I/II Study of Subcutaneously Administered
Veltuzumab (hA20) in NHL and CLL
URL: http://ClinicalTrials.gov/show/NCT00546793
Study 166:
Trial of the Combination of Bevacizumab and
Everolimus in Patients With Refractory, Progressive
Intracranial Meningioma
URL: http://ClinicalTrials.gov/show/NCT00972335
Study 167:
Everolimus (RAD001) for Children With
Chemotherapy-Refractory Progressive or Recurrent
Low-Grade Gliomas
URL: http://ClinicalTrials.gov/show/NCT00782626
Study 168:
Efficacy and Safety of CDP6038 in Patients
With Rheumatoid Arthritis With an Unsuccessful
Response to Anti-Tumor Necrosis Factor
(Anti-TNF) Therapy
URL: http://ClinicalTrials.gov/show/NCT01242488
Study 169:
Study to Assess the Effectiveness of RCHOP With
or Without VELCADE in Previously Untreated
Non-Germinal Center B-Cell-like Diffuse Large
B-Cell Lymphoma Patients
URL: http://ClinicalTrials.gov/show/NCT00931918
Study 170:
Phase III Study of RAD001 Adjuvant Therapy in Poor
Risk Patients With Diffuse Large B-Cell Lymphoma
(DLBCL) of RAD001 Versus Matching Placebo After
Patients Have Achieved Complete Response With
First-line Rituximab-chemotherapy
URL: http://ClinicalTrials.gov/show/NCT00790036
Study 171:
Study of Elacytarabine Versus Investigator’s Choice in
Patients With Late Stage Acute Myeloid Leukaemia
(AML)
URL: http://ClinicalTrials.gov/show/NCT01147939
Study 172:
Single Agent Ofatumumab Vs. Single Agent
Rituximab in Follicular Lymphoma Relapsed After
Rituximab-Containing Therapy
URL: http://ClinicalTrials.gov/show/NCT01200589
Study 173:
Safety and Efficacy Study of TRU-016 Plus
Bendamustine vs. Bendamustine in Relapsed
Chronic Lymphocytic Leukemia
URL: http://ClinicalTrials.gov/show/NCT01188681
Study 174:
Safety and Tolerability Study of PCI-32765 Combined
With Fludarabine/Cyclophosphamide/Rituximab
(FCR) and Bendamustine/Rituximab (BR) in Chronic
Lymphocytic Leukemia (CLL)
URL: http://ClinicalTrials.gov/show/NCT01292135
Study 175:
A Phase 3 Study of Brentuximab Vedotin (SGN-35) in
Patients at High Risk of Residual Hodgkin Lymphoma
Following Stem Cell Transplant (The AETHERA Trial)
URL: http://ClinicalTrials.gov/show/NCT01100502
Study 176:
A Study of ABT-263 in Combination With
Dose-Intensive Rituximab, or Dose-Intensive
Rituximab Alone, in Previously Untreated Patients
With B-Cell, Chronic Lymphocytic Leukemia (CLL)
URL: http://ClinicalTrials.gov/show/NCT01087151
Study 177:
Study of HCD122 (Lucatumumab) and Bendamustine
Combination Therapy in CD40+ Rituximab-refractory
Follicular Lymphoma
URL: http://ClinicalTrials.gov/show/NCT01275209
Study 178:
Safety and Tolerability of XmAb®5574 in Chronic
Lymphocytic Leukemia
URL: http://ClinicalTrials.gov/show/NCT01161511
DEVELOPING CURES, CREATING JOBS • A PARTNERSHIP BETWEEN BIOPHARMACEUTICAL COMPANIES AND STATE RESEARCH INSTITUTIONS
23
Study 179:
Ofatumumab and Bendamustine Combination Therapy
Compared With Bendamustine Monotherapy in Indolent
B-cell Non-Hodgkin’s Lymphoma (NHL) Unresponsive
to Rituximab or a Rituximab-Containing Regimen
URL: http://ClinicalTrials.gov/show/NCT01077518
Study 180:
Eltrombopag Treatment of Thrombocytopenia in
Subjects With Advanced Myelodysplastic Syndrome
(MDS) or Secondary Acute Myeloid Leukemia After
MDS (sAML/MDS)
URL: http://ClinicalTrials.gov/show/NCT00903422
Study 181:
A Study to Determine the Efficacy and Safety of
Lenalidomide in Patients With Mantle Cell NHL Who
Have Relapsed or Progressed After Treatment With
Bortezomib or Are Refractory to Bortezomib. The
“EMERGE” Trial
URL: http://ClinicalTrials.gov/show/NCT00737529
Study 182:
A Phase II Study of Dasatinib in Children and
Adolescents With Newly Diagnosed Chronic Phase
CML or With Ph+ Leukemias Resistant or Intolerant
to Imatinib
URL: http://ClinicalTrials.gov/show/NCT00777036
Study 183:
Dose Escalation, Safety and Pharmacokinetic Study
of SAR103168 in Patients Refractory/ Relapsed Acute
Leukemias or High-risk Myelodysplastic Syndromes
URL: http://ClinicalTrials.gov/show/NCT00981240
Study 184:
Efficacy and Safety of Decitabine as Epigenetic
Priming With Induction Chemotherapy in Pediatric
Acute Myelogenous Leukemia (AML) Subjects
URL: http://ClinicalTrials.gov/show/NCT01177540
Study 185:
A Study of RO5072759 (GA101) in Combination With
CHOP Chemotherapy Versus MabThera/Rituxan
(Rituximab) With CHOP in Patients With
CD20-Positive Diffuse Large B-Cell Lymphoma
URL: http://ClinicalTrials.gov/show/NCT01287741
24
Study 186:
Comparison of Pixantrone + Rituximab With
Gemcitabine + Rituximab in Patients With Aggressive
B-cell Non-Hodgkin Lymphoma Who Have Relapsed
After Therapy and Are Not Eligible for Stem Cell
Transplant
URL: http://ClinicalTrials.gov/show/NCT01321541
Study 187:
Dose Finding Study of Panobinostat Given in
Combination With 5-Azacitidine in Patients With
Myelodysplastic Syndromes (MDS), Chronic
Myelomonocytic Leukemia (CMML) or Acute
Myeloid Leukemia (AML)
URL: http://ClinicalTrials.gov/show/NCT00946647
Study 188:
A Study of GA101 (RO5072759) in Combination With
Chemotherapy in Patients With Previously Untreated
Chronic Lymphocytic Leukemia
URL: http://ClinicalTrials.gov/show/NCT01300247
Study 189:
PK-directed Dose Adjustment of IV Busulfan
Conditioning Regimen for Autologous Stem Cell
Transplant in Lymphoma Patients
URL: http://ClinicalTrials.gov/show/NCT00948090
Study 190:
A Study of YM155 Plus Rituximab in Subjects With
Non-Hodgkin’s Lymphoma Who Have Received Prior
Treatment
URL: http://ClinicalTrials.gov/show/NCT01007292
Study 191:
Panitumumab, Paclitaxel, Carboplatin and 5FU in the
Treatment of Potentially Resectable Gastroesophageal
Adenocarcinoma
URL: http://ClinicalTrials.gov/show/NCT01182610
Study 192:
A Study of Rituximab and Bevacizumab in Patients
With Follicular Non-Hodgkin’s Lymphoma
URL: http://ClinicalTrials.gov/show/NCT00193492
PhRMA • PHARMACEUTICAL CLINICAL TRIALS IN GEORGIA
Study 193:
A Trial of the Combination 5-azacitidine and
Gemtuzumab Ozogamicin Therapy for Treatment of
Relapsed Acute Myeloid Leukemia (AML)
URL: http://ClinicalTrials.gov/show/NCT00766116
Study 194:
A Phase I/II Trial of VR-CHOP in Lymphoma Patients
URL: http://ClinicalTrials.gov/show/NCT00634179
Study 195:
Trial of Nelarabine, Etoposide and Cyclophosphamide
in Relapsed T-cell ALL and T-cell LL
URL: http://ClinicalTrials.gov/show/NCT00981799
Study 196:
Trial of Bendamustine, Bortezomib, and Rituximab
in Patients With Previously Untreated Low Grade
Lymphoma
URL: http://ClinicalTrials.gov/show/NCT01029730
Study 197:
EZN-3042 Administered With Re-induction
Chemotherapy in Children With Relapsed Acute
Lymphoblastic Leukemia (ALL)
URL: http://ClinicalTrials.gov/show/NCT01186328
Study 198:
Ofatumumab for Patients With Previously Untreated
Chronic Lymphocytic Leukemia or Small Lymphocytic
Lymphoma
URL: http://ClinicalTrials.gov/show/NCT01113632
Study 199:
A Phase I Study of AC220 for Children With Relapsed
or Refractory Acute Lymphoblastic Leukemia or Acute
Myelogenous Leukemia
URL: http://ClinicalTrials.gov/show/NCT01411267
Study 200:
Trial Using Cyclophosphamide, Rituximab and
Revlimid (CR2) for the Treatment of Relapsed/
Refractory B-Cell Chronic Lymphocytic Leukemia
(B-CLL) and Small Lymphocytic Lymphoma (SLL)
URL: http://ClinicalTrials.gov/show/NCT01005979
Diabetes
(42 clinical trials recruiting)
Study 1:
A Study in Adults With Type 1 Diabetes
URL: http://ClinicalTrials.gov/show/NCT01421147
Study 2:
A Study in Patients With Type 2 Diabetes Mellitus
URL: http://ClinicalTrials.gov/show/NCT01435616
Study 3:
A Study in Adults With Type 2 Diabetes
URL: http://ClinicalTrials.gov/show/NCT01421459
Study 4:
CAROLINA: Cardiovascular Outcome Study of
Linagliptin Versus Glimepiride in Patients With
Type 2 Diabetes
URL: http://ClinicalTrials.gov/show/NCT01243424
Study 5:
A Study of BMS-512148 (Dapagliflozin) in Patients
With Type 2 Diabetes With Inadequately Controlled
Hypertension on an ACEI or ARB and an Additional
Antihypertensive Medication
URL: http://ClinicalTrials.gov/show/NCT01195662
Study 6:
A Study of BMS-512148 (Dapagliflozin) in Patients
With Type 2 Diabetes With Inadequately Controlled
Hypertension on an Angiotensin-Converting Enzyme
Inhibitor (ACEI) or Angiotensin Receptor Blocker
(ARB)
URL: http://ClinicalTrials.gov/show/NCT01137474
Study 7:
BI 10773 Cardiovascular Outcome Event Trial in
Type 2 Diabetes Mellitus Patients
URL: http://ClinicalTrials.gov/show/NCT01131676
Study 8:
Efficacy and Safety of BI 10773/BI 1356 Fixed Dose
Combination in Treatment naïve and Metformin
Treated Type 2 Diabetes Patients
URL: http://ClinicalTrials.gov/show/NCT01422876
DEVELOPING CURES, CREATING JOBS • A PARTNERSHIP BETWEEN BIOPHARMACEUTICAL COMPANIES AND STATE RESEARCH INSTITUTIONS
25
Study 9:
Safety and Efficacy of BI 10773 and Sitagliptin
Versus Placebo Over 76 Weeks in Patients With
Type 2 Diabetes
URL: http://ClinicalTrials.gov/show/NCT01289990
Study 10:
Exenatide Study of Cardiovascular Event Lowering
Trial (EXSCEL): A Trial To Evaluate Cardiovascular
Outcomes After Treatment With Exenatide Once
Weekly In Patients With Type 2 Diabetes Mellitus
URL: http://ClinicalTrials.gov/show/NCT01144338
Study 11:
Cardiovascular Outcomes Study of Alogliptin in
Subjects With Type 2 Diabetes and Acute Coronary
Syndrome
URL: http://ClinicalTrials.gov/show/NCT00968708
Study 12:
Bardoxolone Methyl Evaluation in Patients With
Chronic Kidney Disease and Type 2 Diabetes
URL: http://ClinicalTrials.gov/show/NCT01351675
Study 13:
Dual Action of Liraglutide and Insulin Degludec in
Type 2 Diabetes: A Trial Comparing the Efficacy
and Safety of Insulin Degludec/Liraglutide, Insulin
Degludec and Liraglutide in Subjects With
Type 2 Diabetes
URL: http://ClinicalTrials.gov/show/NCT01336023
Study 14:
Safety and Efficacy of LX4211 With Metformin in Type
2 Diabetes Patients With Inadequate Glycemic Control
on Metformin
URL: http://ClinicalTrials.gov/show/NCT01376557
Study 15:
A Study With Aleglitazar in Patients With a Recent
Acute Coronary Syndrome and Type 2 Diabetes
Mellitus
URL: http://ClinicalTrials.gov/show/NCT01042769
Study 16:
Efficacy and Safety of TAK-875 in Combination With
Sitagliptin in Participants With Type 2 Diabetes Mellitus
URL: http://ClinicalTrials.gov/show/NCT01414920
26
Study 17:
Welchol as Add-on to Pioglitazone Therapy for Type 2
Diabetes Mellitus
URL: http://ClinicalTrials.gov/show/NCT00789750
Study 18:
Comparison of Technosphere® Insulin Versus Insulin
Aspart in Subjects With Type 1 Diabetes Mellitus Over
a 24-week Treatment Period
URL: http://ClinicalTrials.gov/show/NCT01445951
Study 19:
INV-144 Versus Losartan in Hypertension and Type 2
Diabetes Mellitus Patients With Macroalbuminuria
URL: http://ClinicalTrials.gov/show/NCT01398423
Study 20:
30 Week Parallel Group Comparison Study of
Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg)
qd Versus Respective Monotherapies, Followed by
54 Week Comparison of 5mg+30mg and 5mg+45mg
Versus Respective Monotherapies in Type 2 Diabetes
URL: http://ClinicalTrials.gov/show/NCT01183013
Study 21:
Researching Cardiovascular Events With a Weekly
Incretin in Diabetes (REWIND)
URL: http://ClinicalTrials.gov/show/NCT01394952
Study 22:
A Study in Patients With Type I Diabetes Mellitus
URL: http://ClinicalTrials.gov/show/NCT01454284
Study 23:
12 Week Efficacy and Safety Study of BI 10773 in
Hypertensive Patients With Type 2 Diabetes Mellitus
URL: http://ClinicalTrials.gov/show/NCT01370005
Study 24:
Efficacy and Safety of BI 10773 in Type 2 Diabetes
Patients on a Background of Pioglitazone Alone or
With Metformin
URL: http://ClinicalTrials.gov/show/NCT01210001
Study 25:
Safety and Efficacy of BI 10773 as add-on to Insulin
Regimen in Patients With Type 2 Diabetes Mellitus
URL: http://ClinicalTrials.gov/show/NCT01306214
PhRMA • PHARMACEUTICAL CLINICAL TRIALS IN GEORGIA
Study 26:
Glycemic Control, Safety and Tolerability of TC-6987
Monotherapy in Type 2 Diabetes Mellitus
URL: http://ClinicalTrials.gov/show/NCT01293669
Study 27:
Study Of Safety And Efficacy Of PF-04991532 In
Subjects With Type 2 Diabetes Mellitus
URL: http://ClinicalTrials.gov/show/NCT01336738
Study 28:
An Efficacy, Safety, and Tolerability Study of
Canagliflozin in the Treatment of Patients With Type 2
Diabetes Mellitus With Inadequate Glycemic Control
on Metformin Monotherapy
URL: http://ClinicalTrials.gov/show/NCT01340664
Study 29:
Efficacy and Safety Study of DiaPep277 in Newly
Diagnosed Type 1 Diabetes Adults
URL: http://ClinicalTrials.gov/show/NCT01103284
Study 30:
Liraglutide Effect and Action in Diabetes: Evaluation
of Cardiovascular Outcome Results—A Long Term
Evaluation
URL: http://ClinicalTrials.gov/show/NCT01179048
Study 31:
Comparison of the Efficacy and Safety of Two Intensification Strategies in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin
URL: http://ClinicalTrials.gov/show/NCT01388361
Study 32:
Sitagliptin Cardiovascular Outcome Study
(0431-082 AM1)
URL: http://ClinicalTrials.gov/show/NCT00790205
Study 33:
Safety and Efficacy of BGP-15 in Patients With Type 2
Diabetes Mellitus
URL: http://ClinicalTrials.gov/show/NCT01069965
Study 34:
Study 35:
Pharmacokinetics/Pharmacodynamics of Albiglutide
URL: http://ClinicalTrials.gov/show/NCT01357889
Study 36:
Study to Evaluate the Safety, Tolerability and Efficacy
of Three Dose Levels of Mitoglitazone™ (MSDC-0160)
in Type 2 Diabetic Patients
URL: http://ClinicalTrials.gov/show/NCT01103414
Study 37:
A Phase 2, Placebo-Controlled Study To Evaluate The
Efficacy And Safety Of PF-00489791 In Patients With
Type 2 Diabetes And Overt Nephropathy
URL: http://ClinicalTrials.gov/show/NCT01200394
Study 38:
Prevention of Cystic Fibrosis Diabetes
URL: http://ClinicalTrials.gov/show/NCT00967798
Study 39:
A Study in Patients With Diabetic Kidney Disease
URL: http://ClinicalTrials.gov/show/NCT01113801
Study 40:
Evaluate the Efficacy and Safety of Once Daily
Administration of Atrasentan Tablets (Low and High)
Compared to Placebo in Reducing Residual
Albuminuria in Type 2 Diabetic Patients With
Nephropathy Who Are Treated With the Maximum
Tolerated Labeled Dose of a Renin Angiotensin
System (RAS) Inhibitor
URL: http://ClinicalTrials.gov/show/NCT01356849
Study 41:
Hospital Management of Hyperglycemia Study of
Insulin Glargine Plus Insulin Lispro Versus Human
Regular Insulin
URL: http://ClinicalTrials.gov/show/NCT01136746
Study 42:
Evaluation of Cardiovascular Outcomes in Patients
With Type 2 Diabetes After Acute Coronary Syndrome
During Treatment With AVE0010 (Lixisenatide)
URL: http://ClinicalTrials.gov/show/NCT01147250
Efficacy of BI 10773 Versus Placebo and Sitagliptin
Over 24 Weeks in Patients With Type 2 Diabetes
URL: http://ClinicalTrials.gov/show/NCT01177813
DEVELOPING CURES, CREATING JOBS • A PARTNERSHIP BETWEEN BIOPHARMACEUTICAL COMPANIES AND STATE RESEARCH INSTITUTIONS
27
Heart Disease
(33 clinical trials recruiting)
Study 1:
VIVID—Valvular and Ventricular Improvement Via
iCoapsys Delivery—Feasibility Study
URL: http://ClinicalTrials.gov/show/NCT00512005
Study 2:
A Study of RO4905417 in Patients Undergoing
Coronary Artery Bypass Graft (CABG) Surgery
URL: http://ClinicalTrials.gov/show/NCT01245634
Study 3:
Evaluation of the Safety and Effectiveness of the
CorPath 200 System in Percutaneous Coronary
Interventions (PCI)
URL: http://ClinicalTrials.gov/show/NCT01275092
Study 4:
A Study With Aleglitazar in Patients With a Recent
Acute Coronary Syndrome and Type 2 Diabetes
Mellitus
URL: http://ClinicalTrials.gov/show/NCT01042769
Study 5:
Echocardiography Guided Cardiac Resynchronization
Therapy (EchoCRT)
URL: http://ClinicalTrials.gov/show/NCT00683696
Study 6:
Prevention of Cardiovascular Events (eg, Death From
Heart or Vascular Disease, Heart Attack, or Stroke)
in Patients With Prior Heart Attack Using Ticagrelor
Compared to Placebo on a Background of Aspirin
URL: http://ClinicalTrials.gov/show/NCT01225562
Study 7:
Blazer Open-Irrigated Catheter Clinical Trial
URL: http://ClinicalTrials.gov/show/NCT01253200
Study 8:
Study of the Safety and Efficacy of Apadenoson for
Detection of Myocardial Perfusion Defects Using
SPECT MPI
URL: http://ClinicalTrials.gov/show/NCT00990327
28
Study 9:
Study of the Safety and Efficacy of Apadenoson for
Detection of Myocardial Perfusion Defects Using
SPECT MPI
URL: http://ClinicalTrials.gov/show/NCT01313572
Study 10:
RED-HF™ Trial—Reduction of Events With
Darbepoetin Alfa in Heart Failure Trial
URL: http://ClinicalTrials.gov/show/NCT00358215
Study 11:
A Comparison of Prasugrel and Clopidogrel in Acute
Coronary Syndrome Subjects
URL: http://ClinicalTrials.gov/show/NCT00699998
Study 12:
Cardiovascular Outcomes Study of Alogliptin in
Subjects With Type 2 Diabetes and Acute Coronary
Syndrome
URL: http://ClinicalTrials.gov/show/NCT00968708
Study 13:
Evaluation of Cardiovascular Outcomes in Patients
With Type 2 Diabetes After Acute Coronary Syndrome
During Treatment With AVE0010 (Lixisenatide)
URL: http://ClinicalTrials.gov/show/NCT01147250
Study 14:
VISTA-16 Trial: Evaluation of Safety and Efficacy of
Short-term A-002 Treatment in Subjects With Acute
Coronary Syndrome
URL: http://ClinicalTrials.gov/show/NCT01130246
Study 15:
Post-Myocardial Infarction Remodeling Prevention
Therapy
URL: http://ClinicalTrials.gov/show/NCT01213251
Study 16:
Left Atrial Pressure Monitoring to Optimize Heart
Failure Therapy
URL: http://ClinicalTrials.gov/show/NCT01121107
Study 17:
Cardiovascular Risk Reduction Study (Reduction in
Recurrent Major CV Disease Events)
URL: http://ClinicalTrials.gov/show/NCT01327846
PhRMA • PHARMACEUTICAL CLINICAL TRIALS IN GEORGIA
Study 18:
A Phase 3 Multi-center Study to Assess PET Imaging
of Flurpiridaz F 18 Injection in Patients With CAD
URL: http://ClinicalTrials.gov/show/NCT01347710
Study 19:
AngelMed for Early Recognition and Treatment of
STEMI
URL: http://ClinicalTrials.gov/show/NCT00781118
Study 20:
Six Months Efficacy and Safety of Aliskiren Therapy on
Top of Standard Therapy, on Morbidity and Mortality
in Patients With Acute Decompensated Heart Failure
URL: http://ClinicalTrials.gov/show/NCT00894387
Study 21:
A Multi-center, Placebo-controlled Study to Evaluate
the Safety of GSK716155 and Its Effects on Myocardial
Metabolism, Myocardial Function, and Exercise
Capacity in Patients With NYHA Class II/III
Congestive Heart Failure
URL: http://ClinicalTrials.gov/show/NCT01357850
Study 22:
Increase of Vagal Tone in CHF
URL: http://ClinicalTrials.gov/show/NCT01303718
Study 23:
A Study of RO4905417 in Patients With Non
ST-Elevation Myocardial Infarction (Non-STEMI)
Undergoing Percutaneous Coronary Intervention
URL: http://ClinicalTrials.gov/show/NCT01327183
Study 24:
Clinical Evaluation of Contact™ Therapy™ Cool
Path™ Cardiac Ablation System in Conjunction
With EnSite Velocity Contact™ Technology for the
Treatment of Typical Atrial Flutter
URL: http://ClinicalTrials.gov/show/NCT01401361
Study 25:
The PARTNER II Trial: Placement of AoRTic
TraNscathetER Valves
URL: http://ClinicalTrials.gov/show/NCT01314313
Study 26:
Evaluation of the WATCHMAN LAA Closure Device
in Patients With Atrial Fibrillation Versus Long Term
Warfarin Therapy
URL: http://ClinicalTrials.gov/show/NCT01182441
Study 27:
Clinical Evaluation of Therapy™ Cool Flex™
Irrigated Ablation System for the Treatment of
Typical Atrial Flutter
URL: http://ClinicalTrials.gov/show/NCT01408485
Study 28:
Acute Optimization of Cardiac Resynchronization
Therapy (CRT)Using Echocardiography and SonR
URL: http://ClinicalTrials.gov/show/NCT01293526
Study 29:
RiaSTAP vs. Conventional Transfusion in Patients
Having Heart Valve Surgery
URL: http://ClinicalTrials.gov/show/NCT01283321
Study 30:
Evaluating the Effectiveness of Sildenafil at Improving
Health Outcomes and Exercise Ability in People With
Diastolic Heart Failure (The RELAX Study)
URL: http://ClinicalTrials.gov/show/NCT00763867
Study 31:
Effectiveness of Ultrafiltration in Treating People With
Acute Decompensated Heart Failure and Cardiorenal
Syndrome (The CARRESS Study)
URL: http://ClinicalTrials.gov/show/NCT00608491
Study 32:
A Study on the Pharmacokinetics and Safety of
Valcyte (Valganciclovir) in Pediatric Heart Transplant
Recipients Less Than 4 Months of Age
URL: http://ClinicalTrials.gov/show/NCT01165580
Study 33:
Cardiovascular Safety of Febuxostat and Allopurinol in
Patients With Gout and Cardiovascular Comorbidities
URL: http://ClinicalTrials.gov/show/NCT01101035
DEVELOPING CURES, CREATING JOBS • A PARTNERSHIP BETWEEN BIOPHARMACEUTICAL COMPANIES AND STATE RESEARCH INSTITUTIONS
29
Mental Illness
(87 clinical trials recruiting)
Study 1:
Study of the Safety and Efficacy of Two Fixed Doses
of OPC-34712 as Adjunctive Therapy in the
Treatment of Adults With Major Depressive Disorder
(the Polaris Trial)
URL: http://ClinicalTrials.gov/show/NCT01360632
Study 2:
Safety and Tolerability of Oral OPC-34712 as
Adjunctive Therapy in Adults With Major Depressive
Disorder (the Orion Trial)
URL: http://ClinicalTrials.gov/show/NCT01360866
Study 3:
Long-term Study of Cariprazine in Patients With
Schizophrenia
URL: http://ClinicalTrials.gov/show/NCT01104792
Study 4:
Efficacy in Prevention of Relapse of Schizophrenia in
Subjects Taking Either Placebo or Iloperidone
URL: http://ClinicalTrials.gov/show/NCT01291511
Study 5:
Study of Arbaclofen for the Treatment of Social
Withdrawal in Subjects With Autism Spectrum
Disorders
URL: http://ClinicalTrials.gov/show/NCT01288716
Study 6:
Comparison of Lisdexamfetamine Dimesylate With
Atomoxetine HCl in Attention-Deficit/Hyperactivity
Disorder (ADHD) Subjects With an Inadequate
Response to Methylphenidate
URL: http://ClinicalTrials.gov/show/NCT01106430
Study 7:
Dose-optimization in Adolescents Aged 13-17
Diagnosed With Attention-deficit/Hyperactivity
Disorder (ADHD) Using Extended-release
Guanfacine HCl
URL: http://ClinicalTrials.gov/show/NCT01081132
30
Study 8:
Efficacy & Safety Study of Once-weekly Oral
Aripiprazole in Children and Adolescents With
Tourette’s Disorder
URL: http://ClinicalTrials.gov/show/NCT01418352
Study 9:
Study of Rufinamide in Pediatric Subjects 1 to
Less Than 4 Years of Age With Lennox-Gastaut
Syndrome Inadequately Controlled With Other
Anti-epileptic Drugs
URL: http://ClinicalTrials.gov/show/NCT01405053
Study 10:
A Study to Evaluate the Efficacy and Safety of
Molindone Hydrochloride XR Tablets as Adjunctive
Therapy in Children With Impulsive Aggression
Comorbid With Attention-Deficit/Hyperactivity
Disorder (ADHD)
URL: http://ClinicalTrials.gov/show/NCT01364662
Study 11:
Open-Label, Extension Study to 810P202
URL: http://ClinicalTrials.gov/show/NCT01416064
Study 12:
Efficacy and Safety of Extended-release Guanfacine
Hydrochloride in Children and Adolescents Aged 6-17
Years With Attention-Deficit/Hyperactivity Disorder
(ADHD)
URL: http://ClinicalTrials.gov/show/NCT01244490
Study 13:
A Study of the Safety and Efficacy of Pimavanserin in
Patients With Parkinson’s Disease Psychosis
URL: http://ClinicalTrials.gov/show/NCT01174004
Study 14:
Safety and Tolerability of Aripiprazole in Adolescents
With Schizophrenia or Children and Adolescents With
Bipolar I Disorder, Manic or Mixed Episode With or
Without Psychotic Features.
URL: http://ClinicalTrials.gov/show/NCT01122927
PhRMA • PHARMACEUTICAL CLINICAL TRIALS IN GEORGIA
Study 15:
A Study of the Safety and Tolerability of Pimavanserin
(ACP-103) in Patients With Parkinson’s Disease
Psychosis
URL: http://ClinicalTrials.gov/show/NCT00550238
Study 16:
Melatonin Agonist Effects of Tasimelteon Versus
Placebo in Patients With Major Depressive Disorder
URL: http://ClinicalTrials.gov/show/NCT01428661
Study 17:
Study Evaluating The Efficacy And Safety Of
Bapineuzumab In Alzheimer Disease Patients
URL: http://ClinicalTrials.gov/show/NCT00667810
Study 18:
Major Depressive Disorder With Mixed Features—
Extension
URL: http://ClinicalTrials.gov/show/NCT01423253
Study 19:
Long-term Safety and Tolerability of BMS-820836 in
the Treatment of Patients With Treatment Resistant
Major Depression
URL: http://ClinicalTrials.gov/show/NCT01361555
Study 20:
Continued Safety Monitoring of Solanezumab in
Alzheimer’s Disease
URL: http://ClinicalTrials.gov/show/NCT01127633
Study 21:
Extension Study of the Safety and Efficacy of
Armodafinil Treatment as Adjunctive Therapy in
Adults With Major Depression Associated With
Bipolar I Disorder
URL: http://ClinicalTrials.gov/show/NCT01121536
Study 22:
Efficacy and Safety of Flexibly Dosed BMS-820836 in
the Treatment of Patients With Treatment Resistant
Major Depression
URL: http://ClinicalTrials.gov/show/NCT01309945
Study 23:
SPD489 Adult Major Depressive Disorder (MDD)
Open-label Safety and Tolerability Rollover
Extension Study
URL: http://ClinicalTrials.gov/show/NCT01436175
Study 24:
A Safety and Efficacy Study of 26489112 in Patients
With Treatment-Resistant Major Depressive Disorder
URL: http://ClinicalTrials.gov/show/NCT01114698
Study 25:
A Fixed Dose Study of Adjunctive Treatment to
Antidepressant Therapy for Adults With Major
Depressive Disorder
URL: http://ClinicalTrials.gov/show/NCT01173601
Study 26:
Efficacy, Safety and Tolerability of CX157 in Treatment
Resistant Depression
URL: http://ClinicalTrials.gov/show/NCT01246908
Study 27:
Safety and Efficacy of Lu AA21004 in Adults With
Major Depressive Disorder
URL: http://ClinicalTrials.gov/show/NCT01153009
Study 28:
Efficacy and Safety of Asenapine Treatment for
Pediatric Bipolar Disorder {P06107 Has an Extension
(P05898; NCT01349907}(P06107 AM1)
URL: http://ClinicalTrials.gov/show/NCT01244815
Study 29:
A 6-Month Open-Label Extension Study to the
B2061014 Study to Evaluate the Safety, Tolerability and
Efficacy of DVS SR in the Treatment of Children and
Adolescents With MDD
URL: http://ClinicalTrials.gov/show/NCT01371721
Study 30:
PEARL Schizophrenia Maintenance
URL: http://ClinicalTrials.gov/show/NCT01435928
DEVELOPING CURES, CREATING JOBS • A PARTNERSHIP BETWEEN BIOPHARMACEUTICAL COMPANIES AND STATE RESEARCH INSTITUTIONS
31
Study 31:
A Study to Evaluate the Efficacy and Safety of
Armodafinil Treatment as Adjunctive Therapy in
Adults With Major Depression Associated With
Bipolar I Disorder
URL: http://ClinicalTrials.gov/show/NCT01072929
Study 32:
Study to Evaluate the Efficacy and Safety of
Armodafinil Treatment as Adjunctive Therapy in
Adults With Major Depression Associated With
Bipolar I Disorder
URL: http://ClinicalTrials.gov/show/NCT01072630
Study 33:
Major Depressive Disorder (MDD) With Mixed
Features—Flexible Dose
URL: http://ClinicalTrials.gov/show/NCT01421134
Study 34:
Major Depressive Disorder With Mixed Features
URL: http://ClinicalTrials.gov/show/NCT01423240
Study 35:
Study Evaluating the Safety and Efficacy of
Bapineuzumab in Alzheimer Disease Patients
URL: http://ClinicalTrials.gov/show/NCT00676143
Study 36:
Open-label Study to Compare Hospitalization
Rates of Schizophrenic Patients Treated With Oral
Antipsychotics Versus IM Depot Aripiprazole
(ARRIVE US)
URL: http://ClinicalTrials.gov/show/NCT01432444
Study 37:
Effectiveness and Safety of Flexible Doses of
Paliperidone Prolonged Release in Adolescent Patients
With Schizophrenia
URL: http://ClinicalTrials.gov/show/NCT01009047
Study 38:
Efficacy and Safety Study of Low-Dose Ondansetron
For Adjunctive Therapy In Adult Patients With
Obsessive-Compulsive Disorder
URL: http://ClinicalTrials.gov/show/NCT01275248
32
Study 39:
A Study Of DVS SR In Treatment Of Children
And Adolescent Outpatients With MDD
URL: http://ClinicalTrials.gov/show/NCT01372150
Study 40:
A Study to Evaluate the Efficacy of Paliperidone
Palmitate in the Prevention of Relapse of the
Symptoms of Schizoaffective Disorder
URL: http://ClinicalTrials.gov/show/NCT01193153
Study 41:
Fixed Dose Efficacy and Safety Study of Asenapine
for the Treatment of Schizophrenia in Adolescents
(P05896 AM1)
URL: http://ClinicalTrials.gov/show/NCT01190254
Study 42:
Extension Study to Assess Persistence of Benefit of
LibiGel for the Treatment of Hypoactive Sexual Desire
Disorder (HSDD)
URL: http://ClinicalTrials.gov/show/NCT01235754
Study 43:
Lurasidone—A 24-week Extension Study of Patients
With Bipolar I Depression
URL: http://ClinicalTrials.gov/show/NCT00868959
Study 44:
A Long-Term Safety And Tolerability Extension Study
Of Bapineuzumab In Alzheimer Disease Patients
URL: http://ClinicalTrials.gov/show/NCT00998764
Study 45:
Flexible Dose, Long-term Safety Study of Asenapine
for the Treatment of Schizophrenia in Adolescents
(P05897 AM1)
URL: http://ClinicalTrials.gov/show/NCT01190267
Study 46:
Forced-dose Titration of SPD489 in Adults With
Binge Eating Disorder
URL: http://ClinicalTrials.gov/show/NCT01291173
Study 47:
A Long-Term, Open-Label, Study on Schizophrenia
URL: http://ClinicalTrials.gov/show/NCT01129674
PhRMA • PHARMACEUTICAL CLINICAL TRIALS IN GEORGIA
Study 48:
Study Evaluating The Safety Of AAB-003
(PF-05236812) In Subjects With Alzheimer’s Disease
URL: http://ClinicalTrials.gov/show/NCT01193608
Study 49:
Study Evaluating The Long-Term Safety And Efficacy
Of Subcutaneous Bapineuzumab
URL: http://ClinicalTrials.gov/show/NCT00916617
Study 50:
Open Label Extension Study Evaluating Safety and
Tolerability of AAB-003 (PF-05236812) in Subject
With Mild to Moderate Alzheimer’s Disease
URL: http://ClinicalTrials.gov/show/NCT01369225
Study 51:
Safety, Tolerability, and Efficacy of Cariprazine for
Patients With Bipolar Depression
URL: http://ClinicalTrials.gov/show/NCT01396447
Study 52:
Intramuscular Depot Formulation of Aripiprazole
as Maintenance Treatment in Patients With
Schizophrenia
URL: http://ClinicalTrials.gov/show/NCT00731549
Study 53:
Cariprazine Relative to Placebo in the Prevention of
Relapse of Symptoms in Patients With Schizophrenia
URL: http://ClinicalTrials.gov/show/NCT01412060
Study 54:
Safety and Efficacy of Cariprazine for Bipolar I
Disorder
URL: http://ClinicalTrials.gov/show/NCT01058668
Study 55:
Amyloid Imaging And Safety Study Of
Subcutaneous Bapineuzumab In Subjects With
Mild to Moderate Alzheimer’s Disease
URL: http://ClinicalTrials.gov/show/NCT01254773
Study 56:
NBI-98854 for the Treatment of Tardive Dyskinesia
in Subjects With Schizophrenia or Schizoaffective
Disorder
URL: http://ClinicalTrials.gov/show/NCT01393600
Study 57:
A Study of RO4917838 in Patients With Persistent,
Predominant Negative Symptoms of Schizophrenia
(WN25309)
URL: http://ClinicalTrials.gov/show/NCT01192906
Study 58:
Extension Study of Asenapine {P06107 (NCT01244815)}
for Pediatric Bipolar Disorder (P05898 AM1)
(ADDRESS-98)
URL: http://ClinicalTrials.gov/show/NCT01349907
Study 59:
A 6-Month Extension Study To The B2061032 Study
To Evaluate The Safety, Tolerability, And Efficacy Of
DVS SR In The Treatment Of Child And Adolescent
Outpatients With MDD
URL: http://ClinicalTrials.gov/show/NCT01371708
Study 60:
A Study in Pediatric Patients With Generalized
Anxiety Disorder
URL: http://ClinicalTrials.gov/show/NCT01226511
Study 61:
Efficacy and Safety of Lu AA21004 in Adults With
Major Depressive Disorder
URL: http://ClinicalTrials.gov/show/NCT01179516
Study 62:
Tasimelteon for the Treatment of Non-24-hour
Sleep-Wake Disorder (N24HSWD) in Blind Individuals
With no Light Perception
URL: http://ClinicalTrials.gov/show/NCT01429116
Study 63:
A Study to Evaluate the Safety and Tolerability of
Sublingual Asenapine in a Pediatric Population
With Schizophrenia or Bipolar I Disorder
(Study P06522)
URL: http://ClinicalTrials.gov/show/NCT01206517
Study 64:
A Study of RO4917838 in Patients With
Sub-optimally Controlled Symptoms of Schizophrenia
(NN25307)
URL: http://ClinicalTrials.gov/show/NCT01235520
DEVELOPING CURES, CREATING JOBS • A PARTNERSHIP BETWEEN BIOPHARMACEUTICAL COMPANIES AND STATE RESEARCH INSTITUTIONS
33
Study 65:
Efficacy and Safety of Tasimelteon Compared With
Placebo in Totally Blind Subjects With Non-24-Hour
Sleep-Wake Disorder
URL: http://ClinicalTrials.gov/show/NCT01163032
Study 66:
A Study in Schizophrenia Patients
URL: http://ClinicalTrials.gov/show/NCT01086748
Study 67:
Effect of Lu AA21004 Versus Escitalopram on Sexual
Functioning in Adults With Well-Treated Major
Depressive Disorder
URL: http://ClinicalTrials.gov/show/NCT01364649
Study 68:
Efficacy and Safety Study of SPD489 in Combination
With an Antidepressant in the Treatment of Adults
With Major Depressive Disorder
URL: http://ClinicalTrials.gov/show/NCT01436149
Study 69:
Lamictal as Add-on Treatment for Bipolar I Disorder
in Pediatric Patients
URL: http://ClinicalTrials.gov/show/NCT00723450
Study 70:
A Randomized, Double-blind, Placebo-controlled,
Combined Single Ascending Dose and Multiple
Ascending Dose Study
URL: http://ClinicalTrials.gov/show/NCT01230853
Study 71:
Withdrawal Study to Demonstrate the Maintenance
Effect in the Treatment of Non-24-Hour Sleep-Wake
Disorder
URL: http://ClinicalTrials.gov/show/NCT01430754
Study 72:
A Study of RO4917523 Versus Placebo as Adjunctive
Therapy in Patients With Major Depressive
Disorder and an Inadequate Response to Ongoing
Antidepressant Therapy
URL: http://ClinicalTrials.gov/show/NCT01437657
34
Study 73:
A Study of RO4917838 in Patients With
Sub-optimally Controlled Symptoms of Schizophrenia
(WN25305)
URL: http://ClinicalTrials.gov/show/NCT01235559
Study 74:
Efficacy and Safety Study of SPD489 in Combination
With an Antidepressant in the Treatment of Adults
With Major Depressive Disorder
URL: http://ClinicalTrials.gov/show/NCT01436162
Study 75:
Randomized, Controlled Study Evaluating
CERE-110 in Subjects With Mild to Moderate
Alzheimer’s Disease
URL: http://ClinicalTrials.gov/show/NCT00876863
Study 76:
Efficacy and Safety Study of Lu AA21004 in Adults
With Major Depressive Disorder
URL: http://ClinicalTrials.gov/show/NCT01163266
Study 77:
A Study of RO4917838 in Patients With Persistent,
Predominant Negative Symptoms of Schizophrenia
(NN25310)
URL: http://ClinicalTrials.gov/show/NCT01192867
Study 78:
A Study in Prevention of Re-emergence of Depression
Symptoms
URL: http://ClinicalTrials.gov/show/NCT01299272
Study 79:
A Study to Evaluate the Impact of MABT5102A on
Brain Amyloid Load and Related Biomarkers in
Patients With Mild to Moderate Alzheimer’s Disease
URL: http://ClinicalTrials.gov/show/NCT01397578
Study 80:
A Study of RO4917838 in Patients With Acute
Exacerbation of Schizophrenia
URL: http://ClinicalTrials.gov/show/NCT01234779
PhRMA • PHARMACEUTICAL CLINICAL TRIALS IN GEORGIA
Study 81:
A Study to Assess the Safety and Effect of TC-5214 in
Patients With Major Depressive Disorder
URL: http://ClinicalTrials.gov/show/NCT01288079
Study 82:
A Study of RO4917838 in Patients With Persistent,
Predominant Negative Symptoms of Schizophrenia
(WN25308)
URL: http://ClinicalTrials.gov/show/NCT01192880
Study 83:
A Trial to Explore the Potential Benefit of Safinamide
on Cognitive Impairment Associated With Parkinson’s
Disease
URL: http://ClinicalTrials.gov/show/NCT01211587
Study 84:
Safety and Efficacy of Levomilnacipran SR in Major
Depressive Disorder
URL: http://ClinicalTrials.gov/show/NCT01377194
Study 85:
Efficacy and Safety of Fixed Doses of BMS 820836 in
the Treatment of Patients With Treatment Resistant
Major Depression
URL: http://ClinicalTrials.gov/show/NCT01369095
Study 86:
Safety and Efficacy of Rasagiline in Restless Legs
Syndrome
URL: http://ClinicalTrials.gov/show/NCT01192503
Study 87:
Cocaine Use Reduction With Buprenorphine
URL: http://ClinicalTrials.gov/show/NCT01402492
Stroke
(12 clinical trials recruiting)
Study 1:
Efficacy and Safety Trial of Transcranial Laser
Therapy Within 24 Hours From Stroke Onset
(NEST-3)
URL: http://ClinicalTrials.gov/show/NCT01120301
Study 2:
Efficacy and Safety Study of Desmoteplase to Treat
Acute Ischemic Stroke (DIAS-4)
URL: http://ClinicalTrials.gov/show/NCT00856661
Study 3:
Study Evaluating The Safety And Efficacy Of
PF-03049423 In Subjects With Ischemic Stroke
URL: http://ClinicalTrials.gov/show/NCT01208233
Study 4:
Efficacy and Safety Study of DP-b99 in Treating Acute
Ischemic Stroke
URL: http://ClinicalTrials.gov/show/NCT00893867
Study 5:
Study to Examine the Effects of MultiStem in
Ischemic Stroke
URL: http://ClinicalTrials.gov/show/NCT01436487
Study 6:
Prevention of Cardiovascular Events (eg, Death From
Heart or Vascular Disease, Heart Attack, or Stroke)
in Patients With Prior Heart Attack Using Ticagrelor
Compared to Placebo on a Background of Aspirin
URL: http://ClinicalTrials.gov/show/NCT01225562
Study 7:
Dysport® Adult Lower Limb Spasticity Study
URL: http://ClinicalTrials.gov/show/NCT01249404
Study 8:
Evaluation of the WATCHMAN LAA Closure Device
in Patients With Atrial Fibrillation Versus Long Term
Warfarin Therapy
URL: http://ClinicalTrials.gov/show/NCT01182441
DEVELOPING CURES, CREATING JOBS • A PARTNERSHIP BETWEEN BIOPHARMACEUTICAL COMPANIES AND STATE RESEARCH INSTITUTIONS
35
Study 9:
Cardiovascular Outcomes Study of Alogliptin in
Subjects With Type 2 Diabetes and Acute Coronary
Syndrome
URL: http://ClinicalTrials.gov/show/NCT00968708
Study 10:
Cardiovascular Safety of Febuxostat and Allopurinol
in Patients With Gout and Cardiovascular
Comorbidities
URL: http://ClinicalTrials.gov/show/NCT01101035
Study 11:
Cardiovascular Risk Reduction Study (Reduction in
Recurrent Major CV Disease Events)
URL: http://ClinicalTrials.gov/show/NCT01327846
Study 12:
Gadobutrol Enhanced MRA of the Supra-aortic
Vessels
URL: http://ClinicalTrials.gov/show/NCT01344447
Pharmaceutical Research and Manufacturers of America
950 F Street, NW, Washington, DC 20004
www.phrma.org